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ABSTRACT 
 
Sarah Elizabeth Sinnett: Identification of novel molecules that bind and regulate  
AMP-activated protein kinase (AMPK)  
(Under the direction of Jay Brenman) 
 
 
AMPK is a structurally complex energy sensor allosterically regulated by AMP and 
ADP.  In the presence of energetic stress, AMPK up- and down-regulates catabolic and anabolic 
pathways, respectively, by phosphorylating targets that mediate cytoplasmic signaling and 
proteins that help regulate gene expression.  For years, researchers specializing in cancer and 
type II diabetes have advocated for the discovery of selective AMPK drugs.  To date, however, 
there are no direct AMPK modulators available for patients.  To identify selective AMPK drugs, 
we first published a high-throughput, fluorescence-based assay biased toward the detection of 
molecules that bind the regulatory region of AMPK.  This assay design was based on the premise 
that molecules that bind the AMPK regulatory region may be less likely to bind the conserved 
kinase active site found throughout the kinome.  One of the primary hits identified by this assay 
became the parent molecule for a panel of structural analogs that dose-dependently inhibit 
binding of a fluorescent probe to the AMPK regulatory region.  These analogs have now been 
characterized in orthogonal protein-based and cell-based assays.   
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CHAPTER 1: PAST STRATEGIES AND FUTURE DIRECTIONS FOR IDENTIFYING 
AMP-ACTIVATED PROTEIN KINASE (AMPK) MODULATORS1 
 
Overview 
AMP-activated protein kinase (AMPK) is a promising therapeutic target for cancer, type 
II diabetes, and other illnesses characterized by abnormal energy utilization.  During the last 
decade, numerous labs have published a range of methods for identifying novel AMPK 
modulators.  The current understanding of AMPK structure and regulation, however, has 
propelled a paradigm shift in which many researchers now consider ADP to be an additional 
regulatory nucleotide of AMPK.  How can the AMPK community apply this new understanding 
of AMPK signaling to translational research?  Recent insights into AMPK structure, regulation, 
and holoenzyme-sensitive signaling may provide the hindsight needed to clearly evaluate the 
strengths and weaknesses of past AMPK drug discovery efforts.  Improving future strategies for 
AMPK drug discovery will require pairing the current understanding of AMPK signaling with 
improved experimental designs.   	  
1This chapter was previously published as an article in Pharmacology and Therapeutics and is 
being reused in this dissertation (print and electronic) with permission from Elsevier.  The 
original article is copyrighted by Elsevier.  The original citation is as follows: S. Sinnett and J. 
Brenman. Past Strategies and Future Directions for Identifying AMP-activated Protein Kinase 
(AMPK) Modulators.  Pharmacology and Therapeutics. 2014. doi: 
10.1016/j.pharmthera.2014.02.008. 
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1.  Introduction 
1.1. Physiological roles of adenosine monophosphate-activated protein kinase 
 AMPK is an energy sensor that lies at the nexus of a complex network of anabolic and 
catabolic signaling pathways (Carling, Thornton, Woods, & Sanders, 2012; Hardie, Ross, & 
Hawley, 2012; Russo, Russo, & Ungaro, 2013).  With holoenzymes present in the cytoplasm and 
the nucleus, AMPK can mediate both rapid changes (i.e., phosphorylation of cytoplasmic targets) 
and gradual adjustments (i.e., changes in gene transcription) to maintain energetic homeostasis 
(Fig. 1.1) (Hardie, 2013; Hardie, et al., 2012; Kodiha, Rassi, Brown, & Stochaj, 2007).  As a 
ubiquitously expressed protein complex, AMPK’s regulatory reach extends well beyond the cell 
membrane.  From head to toe, AMPK sustains the energetic demands of the brain, helps muscles 
adapt to strenuous workloads, and regulates hepatic energy stores in response to fasting and 
feasting (Carling, et al., 2012; Moore, Coate, Winnick, An, & Cherrington, 2012; Richter & 
Hargreaves, 2013).  Many investigators have dissected and described AMPK signaling pathways 
in research papers and reviews.  Although descriptions of these pathways fall beyond the scope 
of this review, we encourage clinicians and investigators to revisit these publications (Carling, et 
al., 2012; Hardie, 2013; Hardie, et al., 2012; Russo, et al., 2013). 
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Fig. 1.1. A partial list of AMPK targets.  A. AMPK phosphorylates and inhibits acetyl CoA carboxylase 1 and 2 
(ACC1 and ACC2), resulting in decreased fatty acid synthesis and increased fatty acid oxidation, respectively 
(Hardie, et al., 2012).  CPT1, carnitine palmitoyltransferase 1.  B. AMPK phosphorylates CREB-regulated 
transcription coactivator 2 (CRTC2).  Phosphorylation sequesters the coactivator to the cytoplasm, ultimately down-
regulating gluconeogenesis (Hardie, et al., 2012; Yoon, et al., 2010).  The graphical portrayal of this pathway varies, 
with some authors depicting phosphorylation of CRTC2 by AMPK prior to nuclear export; others depict only 
cytoplasmic phosphorylation (Lee, et al., 2010; Steinberg & Kemp, 2009). 
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1.2. Adenosine monophosphate-activated protein kinase structure and regulation 
AMPK is a conserved serine/threonine kinase expressed in nearly all eukaryotes 
(Miranda-Saavedra, et al., 2007; Russo, et al., 2013). Detailed descriptions of AMPK structure 
and regulation can be found in reviews (Carling, et al., 2012; Hardie, et al., 2012; Russo, et al., 
2013).  In short, AMPK is composed of a catalytic α subunit, a scaffolding β subunit, and a 
regulatory γ subunit (Fig. 1.2) (Russo, et al., 2013).  Mammals express multiple isoforms of each 
subunit (α1, α2, β1, β2, γ1, γ2, and γ3) (Russo, et al., 2013).  Phosphorylation of threonine 172 
(T172) on AMPK-α is required for kinase activity (Carling, et al., 2012; Hardie, et al., 2012) 
(Fig. 1.2).  Upon binding to AMPK-γ, AMP can promote phosphorylation of T172, allosterically 
increase activity of phosphorylated AMPK (p-AMPK), and protect p-AMPK from 
dephosphorylation by protein phosphatases (Fig. 1.2) (Carling, et al., 2012; Hardie, et al., 2012).  
In addition, ADP can inhibit dephosphorylation upon binding to AMPK-γ (Fig. 1.2) (Carling, et 
al., 2012; Hardie, et al., 2012; Xiao, et al., 2011). Finally, phosphorylation and myristoylation of 
AMPK-β have been shown to regulate subcellular distribution of AMPK-β (Fig. 1.2) (Sanz, 
Rubio, & Garcia-Gimeno, 2013).  Other possible AMPK regulatory mechanisms, such as redox 
sensitivity and oligomerization, have also been proposed (Cardaci, Filomeni, & Ciriolo, 2012; 
Scholz, et al., 2009).   
Due to the large number of diverse ligand-binding sites on AMPK, delineating AMPK 
regulatory mechanisms has been challenging for researchers.  Altogether, AMPK has four 
potential adenine nucleotide-binding sites – one site on AMPK-α and three sites on AMPK-γ 
(Carling, et al., 2012; Russo, et al., 2013).  In addition, AMPK-γ has a fourth, constitutively 
unoccupied site with no known function (Carling, et al., 2012; Russo, et al., 2013).  Of the four 
nucleotide-binding sites, no two sites have identical functions or identical ligand binding 
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affinities (Carling, et al., 2012; Gowans, Hawley, Ross, & Hardie, 2013; Russo, et al., 2013; 
Xiao, et al., 2011).  Furthermore, the in vitro binding affinities of these sites vary greatly 
depending on buffer conditions (Xiao, et al., 2007).  This sensitivity to buffer conditions should 
be considered when comparing experimental results across publications.  To illustrate the 
differences among these sites, AMP reversibly binds the allosteric activation site (commonly 
referred to as “Site 1”) and the dephosphorylation inhibition site (commonly referred to as “Site 
3”) with strong and weak affinities, respectively (Xiao, et al., 2011).  In contrast, AMP 
constitutively occupies the remaining binding site on AMPK-γ (commonly referred to as “Site 
4”), while supra-physiological concentrations of AMP must be present to occupy the active site 
on AMPK-α – in which case, AMP would inhibit AMPK (Gowans, et al., 2013; Hardie, et al., 
2012).  Interestingly, point mutation studies have led some researchers to believe that Site 3 
mediates allosteric activation by AMP (Chen, et al., 2012).  Indeed, a crystal structure of AMPK 
prepared with a low concentration of AMP shows binding of AMP to Site 3, but not at Site 1 
(Xiao, et al., 2011).  Regardless of the conflicting data, however, researchers appear to agree that 
the various nucleotide-binding sites on AMPK have distinct regulatory roles and differential 
ligand-binding affinities.  
Researchers had been studying AMPK for over two decades by the time ADP was shown 
to regulate AMPK (Xiao, et al., 2011).  The discovery that ADP protects p-T172 from 
dephosphorylation was historically significant for the AMPK research community, as these 
phosphatase experiments initiated a community-wide conversation about the relative importance 
of AMP and ADP, particularly in vivo where the concentration of ADP exceeds that of AMP 
(Carling, et al., 2012; Gowans, et al., 2013; Oakhill, Scott, & Kemp, 2012; Xiao, et al., 2011).  
Regardless of the relative importance, however, the discovery of ADP’s regulatory role shifted 
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the community’s attention toward a protective regulatory mechanism characterized in 1995, yet 
seldom addressed in the literature for years afterward (Davies, Helps, Cohen, & Hardie, 1995; 
Goransson, et al., 2007; Sanders, Grondin, Hegarty, Snowden, & Carling, 2007; Suter, et al., 
2006).  Instead, researchers often turned to AMPK substrate phosphorylation assays to help 
identify new modulators or characterize known modulators.  The AMPK modulators Compound 
C, A-592107 (the structural pre-cursor of A-769662), and PT1 were all identified in protein-
based activity assays before or concurrent with Xiao et al.’s phosphatase experiments (Anderson, 
et al., 2004; Pang, et al., 2008; Zhou, et al., 2001). The absence of phosphatases biases these 
activity assays toward the identification of molecules that modulate the magnitude of activity and 
away from the identification of molecules that modulate the duration of activity.  Eventually, A-
769662 was shown to both allosterically activate and protect p-AMPK from dephosphorylation 
(Goransson, et al., 2007; Sanders, Ali, et al., 2007).  Is it possible, however, that the inherent bias 
of protein-based activity assays has permitted other potentially useful AMPK drugs to be 
misidentified as false negatives in small molecule screens?  
 
Fig. 1.2. Regulatory mechanisms of AMPK.  The simplified cartoon shows two nucleotide-binding sites on AMPK-
γ.  The remaining sites (Site 2 and Site 4) are omitted for clarity (Carling, et al., 2012; Hardie, et al., 2012; Russo, et 
al., 2013; Sanz, et al., 2013).  
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1.3. Therapeutic applications of adenosine monophosphate-activated protein kinase modulators 
As the umbrella of AMPK regulatory mechanisms has expanded to include 
dephosphorylation inhibition and subcellular localization, the list of potential therapeutic 
applications of AMPK modulators has also grown – both in length and complexity.  Historically, 
attention has been directed primarily toward activating AMPK to treat diabetes (Cool, et al., 
2006; Hardie, 2013; Russo, et al., 2013; Winder & Hardie, 1999; Xie, et al., 2011).  For example, 
the AMPK activators AICAR (the prodrug of ZMP) and A-769662 have been shown to decrease 
blood sugar levels in mouse models of diabetes (Fig. 1.3) (Carling, et al., 2012; Cool, et al., 
2006).  As one may expect, the beneficial effects of pharmacological AMPK activation on 
exercise endurance, blood glucose, and body weight can be inhibited by genetic deletion of a 
single AMPK subunit (Fig. 1.3) (Carling, et al., 2012; Giri, et al., 2006; Halseth, Ensor, White, 
Ross, & Gulve, 2002; Narkar, et al., 2008; Steinberg, et al., 2010).  In addition, cancer biologists 
have shown that, under certain conditions, AMPK activation can inhibit tumor cell proliferation 
and cell growth (Hardie & Alessi, 2013).   
Researchers have also found distinct therapeutic applications for AMPK inhibition.  
Tumor cells, for example, may rely on activated AMPK to survive nutrient-poor, hypoxic 
conditions during solid tumor formation (Hardie & Alessi, 2013; Jeon & Hay, 2012). In addition, 
knockout of both AMPK-α1 and –α2 has been shown to decrease proliferation of astrocytes 
expressing the constitutively active oncogene HrasV12 (Rios, et al., 2013).  Finally, inhibition of 
AMPK by ischemic preconditioning, Compound C (a non-selective AMPK inhibitor), and 
genetic deletion of AMPK-α2 has been shown to reduce infarct volumes in mouse models of 
ischemia (Fig. 1.3) (J. Li, Zeng, Viollet, Ronnett, & McCullough, 2007; Manwani & 
McCullough, 2013; Venna, Li, Benashski, Tarabishy, & McCullough, 2012).   Clearly, there is a 
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need for both inhibitors and activators that directly regulate AMPK.  Unfortunately, the direct 
AMPK inhibitors Compound C and sunitinib are promiscuous; in contrast, direct AMPK 
activators may have poor bioavailability or regulate only a subset of AMPK holoenzymes (Table 
1.1) (Chu, et al., 2007; Karagounis & Hawley, 2009; Kerkela, et al., 2009; Laderoute, Calaoagan, 
Madrid, Klon, & Ehrlich, 2010; Y. Y. Li, et al., 2013; Machrouhi, et al., 2010; Scott, et al., 
2008). 
 
Fig. 1.3.  In vivo studies.  A. The effects of pharmacological activation of AMPK have been studied in models of 
diabetes, obesity, and sedentary lifestyle (Carling, et al., 2012; Cool, et al., 2006; Giri, et al., 2006; Halseth, et al., 
2002; Narkar, et al., 2008; Xie, et al., 2011).  B. Genetic deletion of isoforms has been studied in models of 
energetic stress.  Deleted isoforms are indicated in parentheses (Barnes, et al., 2004; Steinberg, et al., 2010; Venna, 
et al., 2012).  
Table 1.1 (continued on next page).  *cell-free assays; §cell-intact assays; #drugs delivered intraperitoneally, except 
where otherwise noted.  ND, not determined.  1: (Cool, et al., 2006; Goransson, et al., 2007; Sanders, Ali, et al., 
2007; Scott, et al., 2008; Xiao, et al., 2013); 2: (Y. Y. Li, et al., 2013; L. F. Yu, et al., 2013); 3: (J. Li, et al., 2007; 
Machrouhi, et al., 2010; Venna, et al., 2012; Zhou, et al., 2001); 4: (Y. Y. Li, et al., 2013; Pang, et al., 2008);  5: 
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(Cieslik, et al., 2013; Cool, et al., 2006; Corton, Gillespie, Hawley, & Hardie, 1995; Karagounis & Hawley, 2009) ; 
6:  (Chu, et al., 2007; Kerkela, et al., 2009; Laderoute, et al., 2010) 
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2.  Strategies to identify selective adenosine monophosphate-activated protein kinase 
modulators 
2.1. The double-life of the first selective adenosine monophosphate-activated protein kinase 
inhibitor 
Compound C, one of the most commonly used AMPK inhibitors, was first identified in a 
high-throughput kinase assay (Table 1.1) (Zhou, et al., 2001).  Originally described as a 
selective inhibitor, Compound C was eventually shown to inhibit many kinases. (Machrouhi, et 
al., 2010; Zhou, et al., 2001).  Even though AMPK researchers are now well aware of Compound 
C’s promiscuity, many may not realize that Compound C is also sold under the name 
“dorsomorphin”.   The name “dorsomorphin” is derived from the molecule’s ability to regulate 
dorsalization of zebrafish embryos via inhibition of bone morphogenetic protein (BMP) 
receptors (P. B. Yu, et al., 2008).  In agreement with this discovery, another lab published the 
structure of dorsomorphin binding to the ATP-binding site of a type 1 BMP receptor kinase 
(Chaikuad, et al., 2012).  Although the first description of dorsomorphin states that the inhibitor 
is “structurally identical to Compound C”, the term dorsomorphin and its AMPK-independent 
effects during development have seldom been mentioned in AMPK papers, despite the prevalent 
use of Compound C (P. B. Yu, et al., 2008).  
 
2.2. Orthogonal strategies to identify AMPK modulators 
To determine if the structure of Compound C could be optimized to improve selectivity 
for the catalytic site of AMPK-α, researchers simulated binding of Compound C fragments to 
human AMPK-α2 (Machrouhi, et al., 2010).  The fragment-based drug design (FBDD) strategy 
helped generate a collection of molecules that directly inhibited AMPK (Machrouhi, et al., 
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2010). However, of the molecules tested in a kinase selectivity panel, each was shown to 
potently inhibit one or more off-target kinases (Machrouhi, et al., 2010).  Clearly, FBDD did not 
eliminate off-target effects.  The strategy did, however, generate a collection of molecules with 
biased selectivity profiles and, if paired with the right molecular scaffold, could prove to be 
enormously helpful for guiding AMPK drug discovery.   
To realize the full potential of FBDD, one may need to generate in silico fragments for a 
molecule shown to bind not at the highly conserved ATP-binding active site, but at a less 
conserved regulatory site on AMPK.  Candidate binding sites may include regulatory Sites 1 and 
3, the recently discovered binding site for A-769662, or the predicted binding sites for the direct 
activators C24 or PT1 (which have not yet been crystallographically identified!) (Fig. 1.2, Table 
1.1) (Y. Y. Li, et al., 2013; Pang, et al., 2008; Xiao, et al., 2013; L. F. Yu, et al., 2013).  Indeed, 
investigators outside of the AMPK community have already successfully used FBDD to develop 
the anti-tumor molecule ABT-263 (a Bcl-2 family inhibitor) and the anti-coagulant LY517717 (a 
Factor X inhibitor) (Denas & Pengo, 2013; Erlanson, 2012).  Thus, it is possible to use FBDD to 
develop drugs that target different types of ligand-binding sites, including but not limited to 
canonical kinase active sites.  
As an alternative to targeting a single binding site, an in silico or in vitro screen could be 
designed to target a larger regulatory region including multiple known (and perhaps unknown) 
ligand-binding sites. A recently developed high-throughput assay aims to detect small molecules 
that bind AMPK through displacement of a protein-sensitive fluorescent probe shown to bind the 
AMPK regulatory region (Fig. 1.4) (S. Sinnett, J. Sexton, & J. Brenman, 2013).   The rationale 
for this assay was based on insights gained from published crystal structures of mammalian 
AMPK (Xiao, et al., 2007; Xiao, et al., 2011).  These crystal structures were a long-awaited 
	   12	  
milestone for the AMPK community, as they helped to pinpoint the ADP/AMP-binding 
regulatory sites on AMPK-γ (Xiao, et al., 2007; Xiao, et al., 2011).  In addition, the structures 
illustrated the differential ligand-binding affinities of AMPK’s nucleotide-binding sites, 
confirmed that fluorescent coumarin- and methylanthraniloyl (MANT)-labeled nucleotides bind 
AMPK-γ, identified intermolecular interactions between protein residues and bound nucleotides, 
and illustrated the conformation of the AMPK “regulatory fragment”, which is missing the 
kinase active site (Fig. 1.4) (Xiao, et al., 2007; Xiao, et al., 2011).  Equipped with these new 
insights, researchers were then able to design a high-throughput screening assay using MANT-
ADP, a protein-sensitive fluorescent probe that detects competitive binding of ADP to the 
regulatory fragment and full-length AMPK (Fig. 1.4) (S. Sinnett, et al., 2013).  Investigators who 
use this assay to identify molecules that bind full-length AMPK can then confirm that these 
molecules bind the regulatory region in a secondary assay using the regulatory fragment (S. 
Sinnett, et al., 2013).   
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Fig. 1.4.  Protein-sensitive fluorescent probes.  MANT- and coumarin-labeled nucleotides have been used to detect 
binding of molecules to the AMPK regulatory region (S. E. Sinnett, J. Z. Sexton, & J. E. Brenman, 2013; Xiao, et 
al., 2007; Xiao, et al., 2011).  The Markush structure depicts the structure of adenine nucleotides that can be labeled 
with MANT and coumarin moieties.  Note that the MANT moiety can substitute the 2’ or 3’ ribosyl hydroxyl 
(Cheng, Jiang, & Hackney, 1998).  The stylized inset graph shows the protein-sensitive signal of a hypothetical 
probe. 
 
 
 
 
 
 
 
	   14	  
2.3. Unexplored methods 
To facilitate drug discovery, the binding assay described in the previous section must be 
paired with orthogonal studies to determine if molecules that bind AMPK also regulate activity.  
Molecules that bind but have no effect on activity may be candidates for optimization through 
structure-activity-relationship studies (SAR).  If the binding sites are identified, FBDD could 
potentially be used as a tool to guide molecular synthesis.  Structural biologists have made 
strides that may pave the way for the successful application of FBDD. The AMPK community 
now has a wide range of published AMPK structures generated from protein crystals soaked with 
nucleotides and protein co-crystallized with nucleotides (Chen, et al., 2012; Xiao, et al., 2007; 
Xiao, et al., 2013; Xiao, et al., 2011).  The choice of crystallization technique may be important, 
as the soaked AMPK structures counter-intuitively demonstrate no major conformational 
changes upon nucleotide binding (Chen, et al., 2012).  Indeed, investigators have noted 
conflicting data between soaked and co-crystallized structures for other proteins (e.g., the 
signaling molecule p38α and the antiviral protein griffithsin) (Azevedo, et al., 2012; Ziolkowska, 
Shenoy, O'Keefe, & Wlodawer, 2007).  Recently, a group of AMPK researchers concluded that 
AMPK does undergo conformational changes upon nucleotide binding based on their 
comparisons of co-crystallized ATP-bound regulatory fragment (rat α1β1γ1) and AMP-bound 
regulatory fragment (rat α1, human β2, rat γ1) (Chen, et al., 2012).  By comparing both techniques 
against a single holoenzyme, researchers may be able to confirm this conclusion.  For those 
investigators who choose to begin drug discovery projects with in silico FBDD, the use of 
accurate, physiologically representative crystal structures – be they soaked or co-crystallized – 
may prove to be useful for the development of successful drugs.    
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A recent discovery that may expedite AMPK drug discovery is the identification of the 
binding site for the direct activator A-769662 (Xiao, et al., 2013).  Crystallographic data indicate 
that A-769662 binds at the interface between AMPK-α and –β (Xiao, et al., 2013).  In addition, 
researchers have proposed a mechanism explaining how A-769662 can mimic the allosteric 
effects of AMP without binding to AMPK-γ (Xiao, et al., 2013).  The crystal structures of A-
769662 and the AMP-mimetic 991, each bound to p-AMPK, are major milestones for the AMPK 
community, as they are the first to pinpoint a regulatory non-nucleotide binding site in vitro 
(Xiao, et al., 2013).  Now that the binding site for A-769662 has been identified, the AMPK 
community may perhaps look forward to the in vitro confirmation of the predicted binding sites 
for the non-nucleotide modulators C24 and PT1 (Table 1.1).  These new insights into AMPK 
structure and regulation should be strongly welcomed by AMPK researchers directing drug 
discovery efforts.  How can the identification of new ligand-binding sites accelerate translational 
research?  In contrast to the MANT-ADP assay described previously, if researchers design an 
assay that targets a non-nucleotide-binding site, then this second-generation binding assay may 
have a greater chance of helping to identify selective AMPK modulators. Now that the binding 
site for A-769662 has been identified, one may be able to rationally synthesize fluorescent A-
769662 analogs to help detect small molecules that bind AMPK in a mutually exclusive manner.  
If successful, this strategy would identify non-nucleotide-like AMPK-binding molecules that 
would otherwise pass as false negatives in the complementary MANT-ADP assay.  Finally, the 
identification of non-nucleotide-like modulators may be particularly appealing to clinicians, as 
nucleoside analogs (e.g., AICAR) often have poor oral bioavailability (Table 1.1) (Karagounis & 
Hawley, 2009; F. Li, Maag, & Alfredson, 2008).   
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3.  Identification of holoenzyme-sensitive modulators 
3.1. Functional differences among subunit isoforms 
Mammalian AMPK subunits can assemble into twelve distinct heterotrimers, or 
holoenzymes (α1β1γ1, α1β1γ2, α1β1γ3, etc.).  Tissue-specific expression patterns of these 
holoenzymes have been published (Kim & Tian, 2011; Quentin, et al., 2011).  In short, α1, β1, 
and γ1 subunits are moderately to highly expressed in many tissues, including lung, liver, and 
bone; skeletal muscle expresses high levels of α2 and β2 (Kim & Tian, 2011).  Understandably, 
the moderate to high expression levels of α1, β1, and γ1 in many tissues may motivate researchers 
to use purified α1β1γ1 in protein-based assays.  Indeed, the MANT-ADP binding assay described 
earlier was validated and optimized in the presence of α1β1γ1 (Neumann, Woods, Carling, 
Wallimann, & Schlattner, 2003; S. Sinnett, et al., 2013).  Likewise, other publications have used 
α1β1γ1 for a range of in vitro studies, including crystallography, mutagenesis studies, and activity 
assays (Chen, et al., 2012; Neumann, et al., 2003; Sanders, Grondin, et al., 2007).  The frequent 
use of α1-containing complexes is particularly interesting in light of early AMPK research 
indicating that α2-containing complexes from rat liver are more sensitive to allosteric activation 
by AMP (Salt, et al., 1998).  What would happen to AMPK drug discovery efforts if researchers 
routinely tested a panel of AMPK heterotrimers instead of a single holoenzyme?  Could small 
molecules differentially regulate distinct holoenzymes in drug discovery screens?  Would the 
discovery of holoenzyme-sensitive drugs permit researchers to manipulate specific AMPK 
signaling pathways (e.g., cytosolic targets) while leaving other AMPK pathways (e.g., gene 
transcription) unperturbed, thus minimizing unwanted side effects?  The answers depend on 
whether AMPK subunit isoforms are redundant or functionally distinct.   
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Inactivating mutations and genetic deletion of subunit isoforms have been shown to exert 
tissue-specific physiological effects.  Genetic deletion of AMPK-β2 and –γ3, for example, has 
been shown to decrease exercise endurance in mice and inhibit post-exercise glycogen recovery 
in gastrocnemius muscle, respectively (Fig. 1.3) (Barnes, et al., 2004; Steinberg, et al., 2010).  
This result makes intuitive sense, as β2-containing heterotrimers are highly expressed in skeletal 
muscle, and α2β2γ3 has been shown to generate most of the AMPK activity in skeletal muscle 
during high intensity exercise (Birk & Wojtaszewski, 2006).  Similarly, mutations of highly 
conserved residues in AMPK-γ2 have frequently been associated with human cardiomyopathies 
(Fig. 1.5) (Burwinkel, et al., 2005; Liu, et al., 2013; Moffat & Ellen Harper, 2010). Finally, 
deletion of AMPK-α2 has been shown to reduce infarct volume in mouse models of stroke, 
whereas deletion of α1 does not reduce infarct volume (Kim & Tian, 2011; J. Li, Benashski, 
Siegel, Liu, & McCullough, 2010; J. Li, et al., 2007; Steinberg & Kemp, 2009).    
Aside from tissue-specific expression, how can subunits exert isoform-specific 
physiological effects?  Subcellular localization of subunits may reduce redundancy among 
isoforms.  For example, several in vitro techniques have consistently demonstrated differential 
localization of AMPK-α1 and –α2 in insulinoma cells (cytoplasmic versus nuclear, respectively) 
(Salt, et al., 1998).  More recently, researchers demonstrated that leptin-stimulated expression of 
peroxisome proliferator-activated receptor alpha (PPAR-α) was mediated by nuclear 
translocation of AMPK-α2 – but only when α2 was bound to β2 (Suzuki, et al., 2007).  Since the 
expression of PPAR-α has been linked with activation and translocation of a specific AMPK 
subunit isoform, one may now begin to contemplate the therapeutic applications (such as 
treatment of dyslipidemia or diabetes) of a holoenzyme-specific AMPK drug (Ling, Burns, & 
Hilleman, 2012).  
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Fig.	  1.5.	  	  A	  partial	  list	  of	  AMPK-­‐γ2	  mutations	  observed	  in	  patients	  with	  cardiomyopathy	  (Burwinkel,	  et	  al.,	  2005;	  Liu,	  et	  al.,	  2013;	  Moffat	  &	  Ellen	  Harper,	  2010).	  	  These	  mutations	  affect	  residues	  (red)	  that	  are	  highly	  conserved	  throughout	  Eukarya.	  	  CBS,	  cystathionine-­‐β-­‐synthase	  domains	  in	  AMPK-­‐γ.	  	  
19	  	  
3.2. Correlation between disease states and isoform expression profiles 
 When characterizing AMPK under specific physiological conditions (e.g., cancer or 
diabetes), researchers typically measure total AMPK activity and the ratio of p-AMPK to total 
AMPK.  Few publications comprehensively contrast the expression levels of subunit isoforms in 
diseased tissue versus normal control tissue (Table 1.2) (Kim, et al., 2012; C. Li, Liu, Chiu, 
Chan, & Ngan, 2012; Merrill, et al., 2012; Sanli, Linher-Melville, Tsakiridis, & Singh, 2012).  In 
addition, publications typically do not contrast the percent of total AMPK activity contributed by 
each distinct holoenzyme in diseased tissue versus normal tissue.  Would filling in this 
information gap help researchers identify functional differences between isoforms?  If so, would 
AMPK researchers then be able to develop isoform-sensitive drugs that correct metabolic 
abnormalities in diseased tissue while leaving the metabolic pathways in healthy tissue 
unperturbed?  This proposed strategy is similar to a genetic approach researchers recently used 
after observing decreased AMPK-α2 expression in breast tumor tissue versus patient-matched 
non-tumor adjacent tissue (Fox, Phoenix, Kopsiaftis, & Claffey, 2013).  Genetic restoration of 
AMPK-α2 in MCF7 cancer cells (which predominantly express α1) increased cell death in vitro 
and decreased tumor weight in vivo (Fox, et al., 2013).   
 
Table 1.2 (next page) 
*Expression levels compared to those of low sestrin breast cancer control.  #Protein not expressed in cell line.   ND, 
no recorded data; --, no change.  1: (Merrill, et al., 2012); 2: (Kim, et al., 2012); 3: (C. Li, et al., 2012); 4: (Sanli, et 
al., 2012). 
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3.3. Therapeutic applications of holoenzyme-specific modulators 
 During the past decade, AMPK researchers have identified a number of tool compounds 
for in vitro studies and fewer compounds suitable for animal studies (Table 1.1).  To date, no 
one has intentionally designed an assay for the discovery of holoenzyme-specific AMPK 
modulators, but this may change as the list of potential therapeutic applications for holoenzyme-
specific drugs continues to grow.  This review has briefly touched upon a number of isoform-
specific genetic studies whose results suggest therapeutic applications for isoform-sensitive 
modulators (Figs. 1.3, 1.5 and Table 1.2).  These applications include weight management and 
the treatment of ischemia and cancer (Fox, et al., 2013; Giri, et al., 2006; Venna, et al., 2012).  
Forward-thinking researchers may ask: How does one bias drug discovery assays toward the 
identification of isoform-sensitive drugs?   
 
3.4. Past and future discoveries of isoform-sensitive modulators 
In 2004, Abbot Laboratories published a microarrayed kinase activity assay for 
identifying AMPK modulators (Anderson, et al., 2004).  In lieu of assembling assays in wells, 
researchers incubated a gel containing biotinylated substrate peptide and AMPK (pre-incubated 
with compounds) between a 33P-ATP membrane and a streptavidin affinity membrane (SAMTM).  
Importantly, the AMPK used for the screen was purified from rat liver, which expresses high 
levels of AMPK-β1 (Anderson, et al., 2004; Kim & Tian, 2011; Stapleton, et al., 1996).  After 
screening more than 700,000 small molecules, researchers identified 211 hits, including 3 
activators (Anderson, et al., 2004).  One activator, A-592107, became the structural template for 
A-769662 (Cool, et al., 2006).  The development of A-769662 was a milestone for the AMPK 
community, as the drug has since been shown to selectively activate β1–containing holoenzymes 
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in vitro and in vivo at lower doses than those used for other activators (Table 1.1) (Cieslik, et al., 
2013; Corton, et al., 1995; Scott, et al., 2008).  If the microarrayed screen had been performed 
with a β2-containing complex, however, the structural precursor A-592107 may not have been 
discovered.  
This drug discovery case study begs the following questions: Have other modulators been 
incorrectly identified as negative hits due to the choice of AMPK holoenzyme for screening?  
How would one identify new holoenzyme-sensitive modulators?  Preparing multiple 
heterotrimers for parallel screening would be labor intensive.  Theoretically, one could design 
vectors encoding distinct holoenzymes for protein expression and purification.  However, both 
mammalian and bacterial protein expression systems have limitations.  Whereas mammalian cell 
culture may be expensive, bacterial expression systems are unable to post-translationally modify 
AMPK (Oakhill, et al., 2010; Sanz, et al., 2013).  In addition, researchers may worry that the 
conformation of AMPK purified from Escherichia coli may not be physiologically 
representative.  These limitations may push researchers toward screening small molecule 
libraries against AMPK holoenzymes in silico.  Alternatively, a more focused starting point 
could be to rationally synthesize a β2-sensitive modulator using existing crystallographic data.  
Now that the binding site for A-769662 on α2β1γ1 has been crystallographically identified, 
researchers may have an easier time identifying key structural differences between the α-β 
subunit interfaces for β1- and β2-containing heterotrimers.  This in turn may help researchers 
design molecules that are tailored for the α-β2 interface.   
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Summary 
 Today’s community of AMPK researchers is comprised of experts devoted to the 
treatment of cancer, diabetes, cardiomyopathy, and obesity.  Although AMPK literature has 
become increasingly interdisciplinary, a recurring and unifying theme is the demand for potent, 
selective AMPK drugs that can either be administered to patients or be used as tool compounds 
for in vitro studies.  Early drug discovery efforts led to the development of the AMP-mimetic A-
769662 and the discovery of Compound C, an essential inhibitor found in every AMPK lab 
(Cool, et al., 2006; Zhou, et al., 2001).  Since the first appearance of these modulators in the 
literature, biologists have made more strides in AMPK research.  These strides include the 
publication of numerous AMPK structures (soaked and co-crystallized; full-length and truncated; 
phosphorylated and non-phosphorylated) along with the discoveries of ADP’s protective role, the 
first non-nucleotide regulatory binding site, and the first instance of holoenzyme-sensitive 
pharmacological AMPK activation (Chen, et al., 2012; Scott, et al., 2008; Xiao, et al., 2013; 
Xiao, et al., 2011).  With new insights in mind, early small molecule screens can be refined to 
bias drug discovery toward the identification of new molecules with diverse regulatory 
mechanisms.   
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CHAPTER 2: IDENTIFICATION OF SMALL MOLECULES THAT BIND 
THE REGULATORY REGION OF AMPK1 
 
Overview 
AMPK is a conserved heterotrimeric serine-threonine kinase that regulates anabolic and 
catabolic pathways in eukaryotes.  Its central role in cellular and whole body metabolism makes 
AMPK a commonly proposed therapeutic target for illnesses characterized by abnormal energy 
regulation, including cancer and diabetes.  Many AMPK modulators, however, produce AMPK-
independent effects.  To identify drugs that modulate AMPK activity independent of the 
canonical ATP-binding pocket found throughout the kinome, we designed a robust fluorescence-
based high throughput screening assay biased toward the identification of molecules that bind the 
regulatory region of AMPK through displacement of MANT-ADP, a fluorescent ADP analog.  
Automated pintools were used to rapidly transfer small molecules to a low volume assay mixture 
on 384-well plates.  Prior to assay validation, we completed a full assay optimization to 
maximize the signal-to-background and reduce variability for robust detection of small 
molecules displacing MANT-ADP.  After validation, we screened 13,120 molecules and 
identified 3 positive hits that dose-dependently inhibited the protein-bound signal of 
________________________________________________________________________ 
1This	  chapter was previously published as an article in Current Chemical Genomics and 
Translational Medicine.  The original article is copyrighted by Sinnett et al.  The original 
citation is as follows: Sinnett, S.E.; Sexton, J.Z.; Brenman, J.E.  (2013). A High Throughput 
Assay for Discovery of Small Molecules that Bind AMP-activated Protein Kinase (AMPK).  
Curr Chem Genomics and Translational Medicine, 7, 30-38. 
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MANT-ADP in the presence of both full-length AMPK and the truncated “regulatory fragment” 
of AMPK, which is missing the kinase active site.   The average Z’-factor for the screen was 
0.55 and the compound confirmation rate was 60%. Thus, this fluorescence-based assay may be 
paired with in vitro kinase assays and cell-based assays to help identify molecules that 
selectively regulate AMPK with fewer off-target effects on other kinases. 
Introduction 
AMP-activated protein kinase (AMPK) is a heterotrimeric serine-threonine kinase that 
regulates anabolic and catabolic pathways in eukaryotes (Carling, Thornton, Woods, & Sanders, 
2012; Oakhill, Scott, & Kemp, 2012).  AMPK’s ubiquitous expression and central role in cellular 
metabolism have made it a commonly proposed therapeutic target for disorders characterized by 
abnormal energy regulation, including cancer and diabetes (Carling, et al., 2012).  Drugs that 
specifically target AMPK could have immense translational value.  The earliest AMPK 
modulators, AICAR and Compound C, were not specifically developed for AMPK and have off-
target effects (Kim & Tian, 2011; Zhou, et al., 2001).  Compound C, which was identified in a 
library screen for AMPK inhibitors, binds the canonical ATP-binding catalytic site in numerous 
kinases (Handa, et al., 2011; Kim & Tian, 2011; Zhou, et al., 2001).  Strategies designed to 
identify AMPK modulators that target AMPK-unique protein domains, therefore, have the 
theoretical potential to identify molecules that are more selective than those that bind the 
canonical ATP-binding catalytic site found throughout the kinome. 
The mammalian AMPK trimer is composed of one catalytic subunit (α1 or α2) and two 
regulatory subunits (β1 or β2 and γ1, γ2, or γ3) (Carling, et al., 2012; Oakhill, et al., 2012).  
AMPK-γ has four potential nucleotide binding pockets, of which one (Site 2) is constitutively 
unoccupied (Xiao, et al., 2007). Previous studies have identified several modes of AMPK 
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regulation: (1) Phosphorylation of threonine 172 (T172) on AMPK-α activates AMPK; (2) 
Binding of AMP to AMPK-γ (Site 1) allosterically increases activity of p-AMPK by 2 to 5-fold; 
and (3) Binding of AMP or ADP to AMPK-γ (Site 3) inhibits dephosphorylation of p-T172 by 
phosphatases (Oakhill, et al., 2012; Xiao, et al., 2011).  AMP and ADP have also been shown to 
promote the phosphorylation of AMPK, but only when AMPK-β is myristoylated (Carling, et al., 
2012; L. Chen, et al., 2012; Oakhill, et al., 2010; Oakhill, et al., 2011).  Site 4 has been proposed 
to bind AMP in a non-exchangeable manner (Xiao, et al., 2007; Xiao, et al., 2011).  Recent co-
crystallization experiments, however, have shown that nucleotide exchange with ATP is 
possible, though perhaps not physiological (L. Chen, et al., 2012).  Although some researchers 
have disagreed with the designation of Site 3 as the dephosphorylation inhibition site, most 
AMPK researchers agree that AMPK-γ has two primary regulatory nucleotide-binding sites that, 
together, allosterically increase and sustain activity of p-AMPK (L. Chen, et al., 2012; Oakhill, et 
al., 2011; Xiao, et al., 2011). 
Historically, AMP has been thought to be the primary allosteric regulator of p-AMPK 
(Carling, et al., 2012; Sim & Hardie, 1988).  However, ADP’s greater cytosolic abundance and 
ability to inhibit dephosphorylation of p-T172, have led an increasing number of investigators to 
postulate that ADP is the primary allosteric AMPK regulator in vivo (Carling, et al., 2012).  The 
discovery of ADP’s regulatory role was foreshadowed nearly a decade ago, when Chen and 
colleagues demonstrated a correlation between ADP levels and AMPK activity measured from 
human skeletal muscle before and after intense exercise (Z. P. Chen, et al., 2003).   Furthermore, 
these investigators demonstrated that the rise in ADP dwarfed the slight increase in AMP in 
human exercised muscle by 19-fold (Z. P. Chen, et al., 2003).  Given the similar affinities of 
AMP and ADP for the exchangeable AMPK-γ sites (2.5 and 1.5 µM at Site 1, respectively; 80 
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and 50 µM at Site 3, respectively), it is more likely that ADP is the primary regulatory nucleotide 
of AMPK in vivo (Xiao, et al., 2011). Although AMPK-α and AMPK-γ can both bind adenine 
nucleotides, the binding sites on these subunits can have differential affinities for ligands.  For 
example, the non-specific kinase inhibitor staurosporine binds only the single AMPK-α 
canonical catalytic site (Xiao, et al., 2011).  In addition, the environment-sensitive fluorophore 
2’/3’- O- (N’- methylanthraniloyl)-ATP (MANT-ATP) binds two sites on both truncated and 
full-length AMPK, even though full-length AMPK contains three potentially exchangeable 
nucleotide binding sites (Xiao, et al., 2007).  The heterotrimeric truncated AMPK (in contrast to 
full-length AMPK trimer) lacks the canonical ATP-binding site found throughout the kinome 
and is termed the AMPK “regulatory fragment” (Oakhill, Scott, & Kemp, 2009; Xiao, et al., 
2007; Xiao, et al., 2011).  The differential affinities of binding sites on AMPK-α and AMPK-γ 
for various ligands suggests that it may be possible to identify novel AMPK modulators that bind 
the regulatory fragment but not the canonical ATP-binding site found throughout most of the 
kinome.   
We designed a rapid fluorescence-based high throughput assay to identify small 
molecules that would displace MANT-ADP bound to full-length AMPK.  MANT-ADP’s 
fluorescence increases after binding to AMPK, and competitive displacement of bound MANT-
ADP by the primary regulatory nucleotide ADP reverses this increase in fluorescence.  AMPK 
has previously been shown to have two MANT-adenine nucleotide binding sites on the 
regulatory fragment (Saiu, 2010; Xiao, et al., 2007).  This assay could therefore identify 
molecules that compete with MANT-ADP for binding to Site 1 or Site 3 – the exchangeable sites 
on AMPK-γ.  Theoretically, the assay could also identify molecules that bind to an unknown 
allosteric site, provided the binding of the small molecule and MANT-ADP are mutually 
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exclusive.  After screening 13,120 small molecules at less than 5 µM, we identified 3 molecules 
that dose-dependently inhibit MANT-ADP fluorescence in the presence of full-length AMPK 
(the “primary assay/screen”).  We also developed a similar secondary assay using the trimeric 
AMPK regulatory fragment lacking the kinase domain (the “secondary assay/screen”). All 3 
positive hits dose-dependently inhibited MANT-ADP fluorescence in the regulatory fragment 
assay as well.   
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Materials and Methodology 
Materials  
STK740822 (Vitas-M Laboratory, Ltd.), STL035166 (Vitas-M Laboratory, Ltd.), and 
Z64358107 (Enamine, Ltd.) were re-purchased in powder form and then dissolved in DMSO for 
dose response studies.  ADP, lysozyme, and 1% EDTA-free protease inhibitor cocktail were 
purchased from Sigma-Aldrich.  MANT-ADP was purchased from Life Technologies.  Cobalt-
based immobilized metal affinity chromatography (IMAC) resin was purchased from Clontech 
Laboratories, Inc.   
Protein Purification 
Tricistronic vectors encoding full-length AMPK (rat His-α1, β1, γ1) and the AMPK 
regulatory fragment (rat His-α1, 396-548; human β2, 187-272; rat γ1) were gifts from Dr. Uwe 
Schlattner and Dr. Steve Gamblin, respectively.  Vectors were transformed into Rosetta cells and 
individual colonies were then incubated at 37 ⁰C in overnight starter cultures containing 
antibiotics.  Overnight cultures were amplified in auto-inducible media and shaken for two days 
at room temperature.  Induced cultures were pelleted, washed twice in 0.9% NaCl, and then 
sonicated  (40% intensity, 30 seconds, 3 times with 2 minute intervals) at 4 ⁰C in lysis buffer 
containing 50 mM Tris-HCl (pH 8), 100 mM NaCl, 0.75 mg/mL lysozyme, 0.1% Triton X100, 
and 1% EDTA-free protease inhibitor cocktail.  Lysates were centrifuged and supernatants were 
batch-bound onto cobalt-based IMAC resin.  Resin was washed three times in buffer containing 
0.01% Triton X100 (first wash only), 50 mM Tris-HCl (pH 8), 100 mM NaCl, and 2 mM 
imidazole.  Washed resin was loaded onto a column prior to elution in 50 mM Tris-HCl (pH 8), 
100 mM NaCl, and 500 mM imidazole.  Eluates were concentrated on either 30 kDa (for the 
regulatory fragment) or 50 kDa (for full-length AMPK) size exclusion centrifugal filters at 4⁰C.  
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Concentrates were resuspended and concentrated twice more in 50 mM Tris-HCl (pH 8) prior to 
storage at -80 ⁰C.   
Assay Assembly   
Except where otherwise noted, assays were performed with the following conditions: 0.5 
µM full-length AMPK (130 kDa) or 0.5 µM regulatory fragment (66.7 kDa), 0.1 µM MANT-
ADP, 10 mM Tris-HCl (pH 8), 0.45% DMSO (vehicle and negative control), and 5 µM ADP 
(positive control).  Automated assays were assembled in two steps.  First, a NanoQuot (BioTek) 
was used to dispense 11 µL of master mix (protein, MANT-ADP, and Tris-HCl) per well in 
black, low volume 384-well plates (Corning-3676).  Next, a Biomek NX workstation (Beckman-
Coulter, Brea, CA) equipped with pintools (VP Scientific, San Diego CA) was used to transfer 
50 nL of controls (columns 1, 2, 23, and 24) and small molecules (4.5 µM final).  Controls and 
library molecules were transferred from Axygen 384-well rigid PCR plates (Cat no. 321-67-051) 
at 221X concentration for single-concentration screening.   Plates were shaken for 10 minutes 
prior to reading.   
Fluorescence Measurements 
Fluorescence emission spectra of MANT-ADP were collected using a PerkinElmer 
EnSpire plate reader with an excitation wavelength of 360 nm.  Background fluorescence from 
protein was subtracted from the raw data prior to plotting MANT-ADP’s fluorescence in the 
presence of protein.  Fluorescence detection for assay development and screening was performed 
on either a BMG Pherastar Plus (360/10 excitation and 460/10 emission filters) or a PerkinElmer 
EnVision (355/40 excitation and 460/25 emission filters), depending on equipment availability.  
Relative fluorescence units (RFUs) were recorded at room temperature.   
Calculation of Z’   
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Z’ was calculated using the formula:  Z’ = 1- ((3(σvehicle + σADP))/(µvehicle –µADP)) (Zhang, 
Chung, & Oldenburg, 1999). 
Small Molecule Library  
 The Center for Integrative Chemical Biology and Drug Discovery (CICBDD) assembled 
a commercially-available small molecule library from multiple sources comprised of molecules 
that have structural similarities to known kinase inhibitors and/or have been shown to bind 
kinases in silico (Hutti, et al., 2012; Peterson, Janzen, Kireev, & Singleton, 2012).  Library 
molecules were stored at 1 mM concentration in DMSO.  All of the molecules comply with 
Lipinski’s rules (Lipinski, Lombardo, Dominy, & Feeney, 1997).  
Screening Data Analysis 
ScreenAble (ScreenAble Solutions, Chapel Hill, NC) high throughput screening software 
was utilized for merging screening data and chemical structure, for statistical design of 
experiments, and hit selection.  GraphPad Prism was used for non-linear regression analysis of 
dose response data. 
Results 
The overall goal of this study was to identify novel small molecules that preferentially 
bind the regulatory region of AMPK.  To achieve this goal, we designed a fluorescence-based 
assay using purified His-tagged AMPK trimer and a fluorescent analog of AMPK’s primary 
regulatory nucleotide, ADP (Fig. S1).  Optimizing lysis conditions and switching from IPTG-
inducible media to auto-inducible media increased the yield of purified protein from 3 mgs to 20 
mgs per liter of culture, greater than previously published yields for AMPK heterotrimers 
(Neumann, Woods, Carling, Wallimann, & Schlattner, 2003; Rajamohan, et al., 2010; Riek, et 
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al., 2008).  This improved AMPK expression method supplied ample protein for designing and 
optimizing assays, screening libraries, and confirming hits in secondary assays.      
After a thorough review of the available fluorescent nucleotide analogs and assay 
technologies, fluorescent ADP analogs were chosen because of the known physiologic role of 
ADP interaction with AMPK (Oakhill, et al., 2011; Xiao, et al., 2011).   Both MANT-labeled 
and trinitrophenylated (TNP) nucleotide analogs are environment-sensitive probes whose 
fluorescence increases upon binding to nucleotide-binding sites on protein (Fig 2.1A) (Guarnieri, 
Blagg, & Zhao, 2011; Saiu, 2010; Xiao, et al., 2007).  Fluorescence emission spectra were 
recorded for MANT-ADP and TNP-ADP (0.1 µM each) in the presence and absence of protein 
(Figs. 2.1B, S2.2).    Only MANT-ADP fluorescence increased upon addition of full-length 
AMPK and the regulatory fragment (Fig. 2.1B).  MANT-ADP was therefore selected for 
detection of small molecules binding to the regulatory fragment of AMPK.  The general assay 
principle is to pre-load AMPK with MANT-ADP, causing an increase in MANT-ADP 
fluorescence.  If a small molecule can displace MANT-ADP from the binding site, MANT-ADP 
will be ejected and will have a substantial decrease in fluorescence, thereby indicating a positive 
result for the test compound.  Using excess AMPK (0.5 µM protein with 0.1 µM MANT-ADP) 
helped maximize the number of MANT-ADP molecules bound to protein and thus helped 
maximize the protein-bound fluorescent signal in the absence of the competitive positive control 
ADP.   
ADP, which competitively binds to Site 1 and Site 3 on AMPK-γ, inhibited the increase 
in MANT-ADP fluorescence with IC50s of 0.4 µM and 0.3 µM for the regulatory fragment and 
full-length AMPK, respectively (Fig. 2.1C).  For the ADP dose responses, replicates containing 
MANT-ADP with no protein were used as positive controls for 100% inhibition of MANT-
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ADP’s protein-bound fluorescent signal.  Although the signal-to-background ratio was less than 
2-fold (Figs. 2.1B, 2.1D), the assay’s Z’-factor was greater than 0.6 (Fig. 2.1D), indicating that 
the assay was robust enough for high throughput screening.  At an emission wavelength of 460 
nm, full-length AMPK consistently provided a slightly larger assay window, usually resulting in 
higher Z’-factors (Fig. 2.1D).  The small molecule library, therefore, was screened against full-
length AMPK.  Positive hits were confirmed against the regulatory fragment in subsequent 
secondary screens.  Aside from a small difference in assay window, truncation of AMPK-α1 and 
AMPK-β2 did not appear to significantly disrupt interactions among AMPK-γ1, MANT-ADP, 
and ADP.             
 Prior to screening, assay conditions were optimized by testing high and low 
concentrations of several reagents in a design of experiments study using ScreenAble software 
(ScreenAble Solutions, Chapel Hill, NC).  Previous studies have shown that affinities of adenine 
nucleotides for AMPK decrease with increasing ionic strength (Saiu, 2010; Xiao, et al., 2007).  
In agreement with published data, the greatest MANT-ADP fluorescence was observed with a 
low concentration of Tris-HCl (pH 8) and 0 µM NaCl (Fig. 2.2A).  Triton, which is often used to 
prevent adsorption of target proteins onto plastic, had no effect on MANT-ADP fluorescence in 
the presence of 0 µM NaCl (Fig. 2.2A) (Simpson, 2010).  The sacrificial protein BSA did 
increase fluorescence (Fig. 2.2A), but this was due in part to interactions between BSA and 
MANT-ADP.  In the absence of AMPK, MANT-ADP’s fluorescence still increased upon 
addition of BSA, even after subtracting BSA’s autofluorescence from the raw data (Fig. S2.3A).  
It is possible that MANT-ADP binds non-specifically to BSA, thus decreasing the pool of 
MANT-ADP molecules that can bind to AMPK and consequently decreasing the assay window 
between vehicle and ADP-treated control groups (Fig. S2.3B).  Because BSA decreased the 
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assay window and Z’-factor, we decided to exclude BSA from our optimized assay conditions 
(Fig. S2.3B).  Optimized buffer conditions yielded a Z’-factor ≥ 0.6 with an assay window that 
increased linearly with protein and MANT-ADP concentrations (Fig. 2.2B).  Instead of 
increasing AMPK and MANT-ADP concentrations to maximize the assay window, we decided 
to optimize the assay with low reagent concentrations (0.5 µM AMPK and 0.1 µM MANT-ADP) 
to ensure sensitivity for small molecule binding, as micromolar concentrations of AMPK would 
severely limit the theoretical maximum inhibition due to the stoichiometry of enzyme to small 
molecule.    
Since many small molecule libraries use DMSO as a solvent, the DMSO tolerance of the 
optimized assay was determined prior to screening.  The assay yielded a robust Z’ across a range 
of DMSO concentrations, with no statistical difference observed among controls treated with 0-
2% DMSO (Fig. S2.4).  This DMSO tolerance is especially important for automated assay 
assembly, in which the final DMSO concentration may vary depending on the type of robotic 
dispenser used for transferring small molecules.  The DMSO tolerance also allows flexibility in 
starting concentrations of library plate stocks.  
For library screening, a NanoQuot and a Biomek NX workstation were used to dispense 
the assay master mix and small molecules, respectively.  To validate the automated dispensers, 
the plate-to-plate coefficient of variation (CV) was calculated for the control groups on 4 plates 
(< 4% CV between plates; average Z’-factor = 0.6) (Fig. 2.3).  Fluorescence detection was 
performed on a BMG Pherastar Plus, which produced lower signals than the PerkinElmer 
EnVision used for other figures (Figs. 2.1D, 2.2B).  The fold-difference between MANT-ADP’s 
protein-bound and unbound signals, however, was similar for both detectors.  After validating 
minimal plate-to-plate variation, 13,120 molecules from a small molecule library were screened 
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over the course of several days.  Five positive hits (0.04% primary hit rate) were identified, each 
of which inhibited MANT-ADP fluorescence by more than 50% (Fig. 2.4A).  Autofluorescent 
molecules increased the total fluorescent signal and are shown on the scatter plot as having large 
negative binding activity (Fig. 2.4A).  Data for DMSO controls and library molecules had similar 
distributions, with the average compound binding activity close to 0% inhibition of MANT-ADP 
fluorescence (Fig. 2.4B).  The large number of autofluorescent molecules, which decreased the 
efficiency of screening, may explain the low primary hit rate.  It is possible that some of the 
autofluorescent molecules are false negatives that inhibit binding of MANT-ADP but are masked 
by their autofluorescence.  After initial screening, positive hits were re-purchased in powder 
form, dissolved in DMSO and re-tested for inhibition of MANT-ADP fluorescence.  Three of the 
5 positive hits (60% confirmation rate) dose-dependently inhibited MANT-ADP fluorescence in 
the presence of full-length AMPK (Fig. 2.5, Table 2.1).  These 3 hits also dose-dependently 
inhibited fluorescence in the presence of the regulatory fragment (Fig. 2.5, Table 2.1).    Like the 
primary assay using full-length AMPK, the secondary assay was performed in buffer that had 
low ionic strength and was assembled in the same manner, with controls and positive hits added 
to a master mix of regulatory fragment and MANT-ADP.   
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Fig. 2.1.  ADP competes with MANT-ADP for binding to AMPK.  (A) Simplified cartoon showing MANT-ADP 
fluorescence increasing upon binding to protein.  AMPK-α and AMPK-β subunits and additional nucleotide-binding 
sites are omitted for clarity.  (B) MANT-ADP fluorescence increased after addition of regulatory fragment or full-
length AMPK (excitation = 360 nm). Background fluorescence from protein was subtracted from raw data prior to 
plotting the corrected spectra shown above.  A 460 nm emission filter was used for subsequent experiments.  (C) 
ADP inhibited the increase in MANT-ADP fluorescence.  (D) Full-length AMPK provided a slightly greater assay 
window.  Z’-factors > 0.6.  (B-C) n = 5 wells per data point.  (D) n = 6 wells per data point.  Data points are mean ± 
standard deviation.  Some of the standard deviations are too small to be visible when plotted on this scale.  RFUs, 
relative fluorescence units.    
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Fig. 2.2.  Assay optimization. (A) MANT-ADP fluorescence decreased as the ionic strength of the assay solution 
increased.  In the absence of NaCl, 0.01% Triton had no effect on MANT-ADP fluorescence. (B) The assay window 
increased linearly as concentrations of AMPK, ADP, and MANT-ADP were increased at a constant molar ratio.  (A) 
n = 4 wells per data point; (B) n = 6 wells per data point. Data points are mean ± standard deviation.  Z’-factors ≥ 
0.6.  
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Fig. 2.3. Plate-to-plate variation.  Positive and negative controls demonstrate low plate-to-plate variation across 4 
plates.  The average Z’-factor was 0.60 (inset table) and the percentage difference between plates was < 4%.  n = 32 
wells per control group per plate. 
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Fig. 2.4.  High throughput screen.  (A) In a set of sixteen plates from the small molecule library, two of 5120 
molecules inhibited MANT-ADP fluorescence by more than 50% (yellow arrows).  Each plate included 32 positive 
and 32 negative controls (green and red circles, respectively).  Negative inhibition most likely indicates small 
molecule autofluorescence.  Many of the autofluorescent molecules were plotted on a logarithmic y-axis to conserve 
space.  The average Z’-factor for the plates shown above is 0.58.  (B) Histograms and box plots show distribution 
statistics for the positive control ADP (green), vehicle (red), and library molecules (black).  Whiskers indicate the 
range; boxes indicate data between the first and third quartile.    
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Fig. 2.5. Dose-dependent inhibition of MANT-ADP’s protein-bound signal. (A-C)  Three of the five positive hits 
produced sigmoidal dose responses in the presence of full-length AMPK and the regulatory fragment.  DMSO and 
ADP controls were included on each plate and used to define 0 and 100% inhibition, respectively.  n = 5 wells per 
data point.  Data points are mean ± standard deviation.     
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Table 2.1.  Hill slopes, IC50s, and maximum inhibition were calculated for each of the 3 reproducible hits in 
the presence of full-length AMPK and the regulatory fragment (data in parentheses).   
 
 
 
 
 
 
 
 
 
 
 
Table 1.  Hill slopes and IC50s for positive hits 
Positive hit Vendor, catalog number Structure Hill slope IC50,  μM 
1 
 
 
 
Vitas-M Laboratory, Ltd., 
STK740822  
 
 
 
 
  
1.4 (1.4)  
 
2.9 (1.6)  
 
2 
 
 
Vitas-M Laboratory, Ltd., 
STL035166  
 
 
 
 
 
  
1.3 (1.4)  
 
2.7 (1.5)  
 
3 
 
 
Enamine, Ltd., Z64358107  
 
 
 
 
 
 
  
1.1 (2.6)  
 
0.3 (0.2)  
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Discussion 
AMPK’s central role in metabolism makes it an appealing therapeutic target for 
numerous illnesses characterized by abnormalities in energy regulation, such as diabetes or 
cancer (Carling, et al., 2012).   The current widely used AMPK modulators, however, were not 
specifically developed for AMPK and have off-target effects (Kim & Tian, 2011; Zhou, et al., 
2001).  Compound C, which was identified in a library screen for AMPK inhibitors, binds the 
catalytic ATP-binding site and has been shown to be a more potent inhibitor of numerous other 
kinases (Handa, et al., 2011; Kim & Tian, 2011; Machrouhi, et al., 2010; Zhou, et al., 2001).  
Furthermore, Compound C’s selectivity may be over-estimated in AMPK literature, as many 
papers fail to mention Compound C’s alternate identity as the bone morphogenetic protein 
receptor modulator, dorsomorphin (Yu, et al., 2008).  In contrast to molecules that bind the 
canonical catalytic ATP-binding pocket found throughout the kinome, molecules that bind the 
regulatory region of AMPK may be more selective and could be extremely useful as either drugs 
or as tool compounds for analysis of AMPK function in vivo.  It is important to note that both 
Site 1 and Site 3 bind AMP, ADP, and ATP (Xiao, et al., 2011).  Small molecules that bind the 
regulatory region of AMPK may, therefore, include ATP-competitive ligands.  The ideal 
discovery would be that of ATP-competitive modulator that binds Site 1 and/or Site 3, but not 
the kinase active site.  The preferential binding of staurosporine to the kinase active site indicates 
differential affinities of these three ATP-binding sites for small molecules (Xiao, et al., 2011).   
To identify molecules that bind the regulatory region of AMPK, we designed a 
fluorescence-based assay using readily purified His-tagged protein and commercially available 
MANT-ADP, an analog of AMPK’s primary regulatory nucleotide (Carling, et al., 2012).  
Binding of MANT-labeled analogs to nucleotide-binding sites on protein can be easily detected 
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by an increase in fluorescence (Xiao, et al., 2007).  No crystal structures of AMPK with MANT-
ADP have been published, but structures of the regulatory fragment soaked with MANT-AMP 
indicate binding at Sites 1 and 3 (Saiu, 2010).  Because full-length AMPK provided a slightly 
larger assay window in preliminary experiments, we decided to use full-length AMPK for our 
primary screen and the regulatory fragment for our secondary screen.  Although full-length 
AMPK has three available nucleotide binding sites (one on AMPK-α and two on AMPK-γ), 
fluorescence studies have shown that MANT-ATP binds only two sites on both the regulatory 
fragment and full-length AMPK (Xiao, et al., 2007).    Because our assay measures MANT-ADP 
fluorescence and not enzyme activity, the assay could identify positive hits that may be 
overlooked by peptide phosphorylation kinase assays.  Kinase assays, such as the ones used to 
identify the drugs Compound C and A-592107, are biased toward the identification of ATP-
competitive inhibitors that bind AMPK-α and AMP-mimetics that increase the activity of p-
AMPK, respectively (Anderson, et al., 2004; Cool, et al., 2006; Zhou, et al., 2001).  (A-592107 
was later used as a structural template for the optimized synthetic analog A-769662, but this drug 
was shown to be ineffective against AMPK heterotrimers containing AMPK-β2 (Cool, et al., 
2006; Treebak, Birk, Hansen, Olsen, & Wojtaszewski, 2009).)   Because purified protein 
phosphatases are not included in kinase activity assays, these assays are biased away from the 
identification of protective ADP-mimetics (Zhou, et al., 2001).  Our fluorescence-based assay, 
on the other hand, can identify molecules that displace MANT-ADP.  Orthogonal follow-up 
assays, including in vitro assays in the presence of phosphatases, can then determine if positive 
hits are allosteric inhibitors, allosteric activators, dephosphorylation inhibitors, or candidates for 
structure-activity relationship (SAR) optimization. 
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To optimize MANT-ADP’s protein-bound fluorescent signal, we tested 16 unique assay 
mixtures in a full-factorial screening design of experiments study (Fig. 2.2A).  We subsequently 
decided to minimize our assay’s ionic strength to increase the protein-bound signal of MANT-
ADP.  Our full-factorial data agrees with Saiu’s and Xiao et al.’s data, which show an inverse 
relationship between salt concentration and nucleotide binding affinities for AMPK-γ (Saiu, 
2010; Xiao, et al., 2007). Published nucleotide binding studies have, in fact, been performed in 
low ionic strength conditions (Xiao, et al., 2007).  Further characterization of positive hits from 
this assay should, however, be completed under more physiological conditions.   
Although increasing concentrations of MANT-ADP and AMPK would have produced a 
larger assay window, we decided to continue with low concentrations of each so that all MANT-
ADP-binding sites would be saturated by positive hits when screening libraries at 5 µM or less 
(Fig. 2.2B).  Instead of maximizing the Z’-factor, we prioritized the sensitivity of the assay to 
small molecule detection.  Despite the low signal-to-background ratio, the assay was robust and 
identified positive hits that dose-dependently inhibited MANT-ADP fluorescence.  It is 
important to note that our experiments used a standard Coumarin (360nm excitation and 460 nm 
emission) filter set.  The greatest difference between MANT-ADP’s bound and un-bound 
signals, however, occurs close to 440 nm (Fig. 2.1B).  Switching from a 460 nm to a 440 nm 
filter could be an alternative way to increase the assay window and/or Z’-factor without changing 
the biochemistry, but has the disadvantage of potentially increasing the interference of 
autofluorescent compounds in the near-ultraviolet range.   
One substantial drawback to using MANT-ADP as a fluorescent probe is the potential for 
false negatives due to the high percentage of autofluorescent compounds near 460 nm (Jarecki, et 
al., 2005; Larsen, Zylka, & Scott, 2009; Martin, et al., 2012).  Thus, our assay cannot distinguish 
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between fluorescent true negatives and fluorescent false negatives that inhibit binding of MANT-
ADP to AMPK.  A red-shifted fluorophore, such as TNP-ADP, could reduce this problem.  
Substitution of 0.1 µM MANT-ADP with 0.1 µM TNP-ADP, however, failed to produce an 
assay window (Fig. S2.2).  Furthermore, trinitrophenylation replaces both of the ribosyl hydroxyl 
groups on nucleotides (Hiratsuka & Uchida, 1973).  Because these hydroxyl groups form 
hydrogen bonds with aspartate residues on AMPK-γ, trinitrophenylation could decrease the 
affinity of adenine nucleotides to AMPK-γ (L. Chen, et al., 2012; Saiu, 2010).  In their 
discussion of a TNP-ATP-based screening assay, Guarnieri et al. suggested using MANT-ATP 
as an alternative because TNP-ATP had such a weak binding affinity to their target kinase 
(Guarnieri, et al., 2011).  To compensate for TNP-ATP’s high KD, the authors increased their 
probe, protein, and library concentrations to 150, 100, and 100 µM, respectively (Guarnieri, et 
al., 2011).  Indeed, we had to increase TNP-ADP to 100 µM to observe a window between the 
probe’s protein-bound and unbound fluorescent signals (Fig. S2.2).  A better probe may be a red-
shifted Alexa Fluor-ADP analog that retains one of the ribosyl hydroxyls needed for binding.  
Alexa Fluor-ADP is not environment-sensitive, however, so one would need to use fluorescence 
polarization to detect binding of the probe to AMPK.   
Finally, our library screen yielded a relatively low hit rate of 0.04% with a 60% 
confirmation rate.  Multiple factors may have contributed to our low hit rate.  First, nearly one-
fourth of our library molecules produced fluorescent signals that were higher than the average 
DMSO control signal and, therefore, limited the screening efficiency, thereby lowering the hit 
rate.  These molecules, which are shown on our scatter plot as having negative inhibition (Fig. 
2.4), are most likely autofluorescent and may include false negatives that inhibit binding of 
MANT-ADP to AMPK.  It is unlikely that these molecules could be increasing fluorescence by 
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promoting interactions between AMPK and MANT-ADP, as the protein concentration exceeds 
the MANT-ADP concentration by almost 5-fold.  Any MANT-ADP molecules that dissociate 
from one AMPK heterotrimer should bind immediately to another heterotrimer.  Finally, the 
small molecule library we screened herein includes molecules that were pre-selected based on 
structural similarities to known kinase inhibitors and could, therefore, bind kinase domains 
(Hutti, et al., 2012; Peterson, et al., 2012).  If MANT-ADP binds only the nucleotide-binding 
sites on AMPK-γ, then the assay will be biased toward the discovery of small molecules that 
bind the regulatory region of AMPK and away from the discovery of promiscuous kinase 
modulators that bind the canonical, catalytic ATP-binding pocket found throughout the kinome.  
Our low hit rate, therefore, may reaffirm this bias and may be much lower than the hit rate for 
future screens of more diverse small molecule libraries.   
Conclusion 
This screen has identified small molecules that are capable of inhibiting MANT-ADP’s 
protein-bound fluorescent signal. Small molecules that dose-dependently inhibit MANT-ADP 
fluorescence may include AMPK inhibitors or activators.  Orthogonal follow-up studies with 
these molecules will demonstrate if they can also displace ADP and will be performed both 
biochemically in vitro and then in cell lines for AMPK modulation in a cell intact physiological 
environment.  Positive hits that bind the regulatory fragment but do not regulate AMPK may be 
used as structural templates for SAR optimization.  Ultimately, the best way to determine if these 
molecules actually regulate AMPK is to test them in both cell-based assays and in vitro kinase 
assays before evaluating in vivo function.     
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Supplementary Material 
 
 
Fig. S2.1.  AMPK-β and AMPK-γ subunits co-eluted with His-tagged AMPK-α.  In agreement with published data, 
rat AMPK-β1 and rat AMPK-γ1 have similar apparent molecular weights (Neumann, et al., 2003). 
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Fig. S2.2.  TNP-ADP’s emission spectra showed no difference between unbound and protein-bound signals when 
TNP-ADP was present at a low 0.1 µM concentration.  A small assay window was observed when the concentration 
of TNP-ADP was increased to 100 µM.  n = 5 wells per data point.  Data points are mean ± standard deviation.   
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Fig. S2.3. (A) MANT-ADP fluorescence increased in the presence of BSA.  Background fluorescence from BSA 
was subtracted from raw data prior to plotting the points shown above.  n = 3 wells per data point.  (B) The assay 
window decreased with increasing concentrations of BSA.  (A) n = 3 wells per data point; (B) n = 4 wells per data 
point.  Data points are mean ± standard deviation. 
  
 
Fig. S2.4. Full-length AMPK tolerated 0-2% DMSO. n = 6 wells per data point.  Data points are mean ± standard 
deviation.
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CHAPTER 3: IDENTIFICATION OF NOVEL AMP-ACTIVATED PROTEIN KINASE 
(AMPK) MODULATORS CONTAINING A COMMON STRUCTURAL SCAFFOLD1 
 
 
Overview 
 
We recently published the design of a high-throughput fluorescence-based assay for the 
identification of molecules that bind AMP-activated protein kinase (AMPK).  This assay 
identified 3 molecules that dose-dependently inhibited the protein-bound signal of the 
fluorescent probe methylanthraniloyl-ADP (MANT-ADP) in the presence of both full-length 
AMPK and the AMPK regulatory fragment, which is missing the AMPK kinase domain.  After 
identifying these 3 molecules, we used a similarity screen followed by rational synthesis to 
generate an expanded list of positive hits containing a common structural scaffold.  Routine 
testing for false positive hits confirmed that the expanded list of analogs included no thiol-
reactive molecules and no small molecule aggregators.  We then used kinase activity assays, 
phosphatase assays, and cell-intact assays to determine if these analogs regulate AMPK.  Of the 
9 molecules tested in orthogonal assays, 4 analogs dose-dependently regulated the 
phosphorylation state and/or activity of purified phospho-AMPK.  One analog consistently  
 
 
1This thesis will be embargoed for two years so that the research described in Chapters 3-4 can 
first be published in a journal.    
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inhibited AMPK activity in both protein-based and cell-based assays.  In addition to identifying a 
novel AMPK inhibitor, these results validate the use of our fluorescence-based binding assay as 
a tool for the discovery of new molecules that modulate AMPK activity through multiple 
regulatory mechanisms.
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Introduction 
 AMPK is a metabolic regulator that maintains energetic homeostasis in eukaryotes 
(Hardie, 2013; Hardie, Ross, & Hawley, 2012).  For years, researchers have advocated for the 
development of selective AMPK drugs to help treat cancer and diabetes (Hardie, 2013).  Many 
commonly used AMPK modulators, however, have off-target effects and/or poor bioavailability 
(Sinnett & Brenman, 2014).   To help identify new AMPK drugs, we published a high-
throughput assay that detects binding of small molecules to AMPK by displacement of the 
fluorescent probe methanylanthraniloyl-ADP (MANT-ADP) (Sinnett, Sexton, & Brenman, 
2013).  ADP is a key regulatory nucleotide for AMPK and has been shown to bind 2 sites on the 
regulatory AMPK-γ subunit (Xiao, et al., 2011).  A binding assay biased toward the discovery of 
molecules that bind the AMPK regulatory region may be less likely to identify promiscuous 
molecules that bind the conserved kinase active site (Sinnett, et al., 2013). 
 Unlike the commonly used kinase assay, a binding assay may identify a wider range of 
potential AMPK modulators.  Whereas a purified kinase assay can identify molecules that 
regulate the magnitude of AMPK activity, a binding assay may identify molecules that are 
subsequently shown to regulate the magnitude and/or duration of AMPK activity (Sinnett & 
Brenman, 2014).  For example, physiological concentrations of ADP have no effect on the 
activity of purified p-AMPK (Carling, Clarke, Zammit, & Hardie, 1989).  In a phosphatase 
assay, however, ADP can protect phospho-threonine 172 (p-T172) on the catalytic AMPK-α 
subunit from dephosphorylation (Xiao, et al., 2011).  Phosphorylation of T172 is essential for 
AMPK activation and ADP protects p-T172 via binding to one of 3 nucleotide-binding sites on 
the regulatory AMPK-γ subunit (AMPK- γ has a fourth putative binding site, but this site has 
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been constitutively empty in all crystal structures published thus far) (Hardie, et al., 2012; Xiao, 
et al., 2011).  
 After screening over 13,000 small molecules, we identified 3 hits that dose-dependently 
inhibited binding of MANT-ADP to full-length AMPK and the AMPK regulatory fragment, 
which includes regulatory nucleotide-binding sites but not the ATP-binding kinase active site 
(Sinnett, et al., 2013).  Before characterizing our published positive hits in activity assays, we 
decided to eliminate potential false positive hits from further study.  Three classes of false 
positive inhibitors that can be identified in protein-based assays are small molecule aggregators, 
thiol-reactive molecules, and redox cycling molecules (Coan, Maltby, Burlingame, & Shoichet, 
2009; Feng & Shoichet, 2006; Huth, et al., 2005; Johnston, 2011).  One may easily eliminate 
false positive aggregators and thiol-reactive molecules by repeating the protein-based assay in 
the presence of Triton X-100 or DTT, respectively (Bharat, Blanchard, & Brown, 2013; Feng & 
Shoichet, 2006; Montaudon, et al., 2007). The inclusion of DTT in primary screening assays, 
however, requires careful consideration because DTT can react with redox cycling molecules to 
generate hydrogen peroxide (Johnston, 2011).  Hydrogen peroxide can in turn inhibit enzymes in 
high-throughput screening assays (Johnston, 2011).  Our published binding assay, however, 
included no reducing agents (Sinnett, et al., 2013).  We therefore decided to re-test positive hits 
in the presence of DTT and Triton to eliminate potential thiol-reactive molecules or aggregators, 
respectively.   
One of our published hits, molecule STK740822, produced similar binding curves in the 
presence and absence of 1 mM DTT and 0.01% Triton.  To improve our chances of discovering a 
novel AMPK modulator, we generated an expanded list of AMPK-binding molecules that are 
structurally similar to the parent molecule STK740822.  After testing these molecules in 
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orthogonal assays, we identified 4 analogs that dose-dependently regulated the phosphorylation 
state and/or activity of p-AMPK.  Furthermore, the analog STK823366 dose-dependently 
inhibited AMPK in protein-based and cell-based assays.  Thus, our fluorescence-based binding 
assay can be used as a first step to help identify molecules that regulate AMPK via multiple 
mechanisms.  
66	  	  
Methods 
 Reagents.  BAS 02250954 and BAS 03338548 were purchased from Asinex; STK823366 
and STK740822 were purchased from Vitas-M Laboratory, Ltd.  Dave Musso at NCCU 
synthesized the remaining analogs.  A-769662, Compound C, and ADP were purchased from 
Tocris, Calbiochem, and Sigma, respectively.  Small molecules were dissolved in DMSO (except 
where otherwise noted) and stored at -20 °C.   
Primary antibodies were purchased from Cell Signaling (except where otherwise noted); 
secondary antibodies were purchased from Li-Cor Biosciences.  Antibodies were diluted in 1x 
TBS with 5% BSA, 0.1% Tween-20, 0.02% sodium azide, and 0.02% SDS (for secondary 
antibodies only).  
His-tagged AMPK.  Full-length AMPK (rat His-α1, β1, γ1) and regulatory fragment 
(mammalian His-α1, β2, γ1) were purified according to published methods (Sinnett, et al., 2013).  
Eluted regulatory fragment and full-length His-AMPK (intended for use in binding assays) were 
concentrated (20 mg/mL) and stored at -80 °C in 50 mM Tris (pH 8.2).  Full-length AMPK 
intended for use in phosphatase and kinase assays was purified, mixed with GST-CaMKKβ, and 
allowed to react for 30 minutes at 22 °C (Tokumitsu, Iwabu, Ishikawa, & Kobayashi, 2001).  
Concentrations of AMPK and GST-CaMKKβ in the phosphorylation reaction were 7 mg/mL and 
63 µg/mL, respectively. Reaction conditions were derived from a previously published paper 
(Chen, et al., 2009).  Glutathione Sepharose 4B resin was used to remove GST-CaMKKβ from 
the reaction mixture.  Phosphorylated His-AMPK was further polished on a Sephacryl S-200 
column, concentrated in 50 mM Tris (pH 8.2, 20 mg/mL protein), and stored at -80 °C.  Because 
Tris buffer is not recommended for isothermal titration calorimetry (ITC), full-length His-AMPK 
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intended for ITC was purified, concentrated, and immediately frozen in 50 mM phosphate buffer 
(pH 7.4) (Pierce, Raman, & Nall, 1999).  
GST-calcium/calmodulin-dependent protein kinase kinase β (GST-CaMKKβ).   The 
construct used to express GST-CaMKKβ has been previously published (Tokumitsu, et al., 
2001).  The purification methods referenced for His-tagged AMPK were adapted for the 
purification of GST-CaMKKβ (Sinnett, et al., 2013).  GST-tagged protein was eluted with 20 
mM glutathione from Glutathione Sepharose 4B resin.  Eluate was stored at -20 °C (10 mg/mL, 
50% glycerol, 25 mM Tris pH 8.2).   
GST-acetyl CoA carboxylase (GST-ACC) peptide.2  Primers coding for residues 
surrounding Ser79 of rat ACC1 preceded by a five-residue polyglycine linker were annealed and 
ligated into the BamHI and XhoI sites of pGEX-4T-1. The resulting plasmid was transformed 
into Rosetta cells for protein expression in autoinduction media.  Cell growth and lysis 
conditions were completed according to published methods (Sinnett, et al., 2013).  The lysate 
was centrifuged to pellet debris.  Clarified supernatant was then filtered and incubated with 
Glutathione Sepharose 4B resin.  The peptide was eluted with 20 mM glutathione in lysis buffer.  
Eluate was concentrated and buffer-exchanged into 50 mM Tris-Cl (pH 8.2) before being stored 
at 20 mg/mL at -80 °C.  The peptide sequence (including the polyglycine linker) added to the 
GST tag was GGGGGLAFHMRSSMSGLHLVKQGRDRKK.  Ser79 (underlined) is 
phosphorylated by AMPK.   
 
2These independently designed methods are similar to published methods describing the use of 
GST-ACC peptide for AMPK assays.  For example, see Scott et al., Protein kinase substrate 
recognition studied using the recombinant catalytic domain of AMP-activated protein kinase and 
a model substrate, J Mol Biol, 2002, 317(2): 309-23. 
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His-protein phosphatase 2C alpha (His-PP2Cα).  His-PP2Cα was purified according to 
the methods referenced above for His-tagged AMPK and then stored (17 mg/mL) at -20 °C in 
50%  glycerol, 25 mM Tris (pH 8.2) (Sinnett, et al., 2013).  This construct has been previously 
published (Marley, et al., 1996). 
Binding assays.  Except where otherwise noted, assay assembly and data analysis were 
completed according to published methods (Sinnett, et al., 2013).  Binding assays were manually 
assembled, with the exception of the similarity screen.  Automated assembly of the similarity 
screen was completed according to published methods (Sinnett, et al., 2013).  Analogs were 
cherry-picked from a 10 mM Asinex small molecule library and a 0.5 mM kinase focused 
library, which has been described previously (Sinnett, et al., 2013).  Molecules were screened at 
a final concentration of 45 and 2.3 µM, respectively. 
ITC.  A MicroCal Auto-Itc200 system (GE Healthcare, Pittsburgh, PA) was used to study 
binding interactions between ADP and full-length His-AMPK at room temperature in the 
presence of 5 mM phosphate buffer (pH 7.4).  To decrease the ionic strength of the buffer, full-
length AMPK frozen in 50 mM phosphate buffer was thawed, diluted in 5 mM phosphate buffer 
(pH 7.4) and then concentrated via centrifugal filtration.  At the start of the ITC experiment, the 
concentrations of His-AMPK (in the sample cell) and ADP (in the syringe) were 70 µM and 1.4 
mM, respectively.   
Kinase assays.  Assay conditions were adapted from published methods (Neumann, 
Woods, Carling, Wallimann, & Schlattner, 2003).  The final assay buffer was comprised of 40 
mM Hepes (pH 7.4), 5 mM MgCl2, 200 µM ATP, 75 mM NaCl, 0.01% Triton X-100, 1 mM 
DTT, and 0.45% DMSO (vehicle).  Because some analogs had poor solubility at high 
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concentrations, all analogs and controls were diluted in assay buffer and centrifuged (1 min, 
5000 rpm, 4 °C) to remove insoluble matter.  GST-ACC peptide and p-AMPK were thawed, 
diluted in assay buffer, and then added to the supernatant at final concentrations of 900 and 0.1 
ng/µL, respectively.  Kinase assays were assembled on ice; reactions were allowed to proceed 
for 30 minutes at room temperature.  Reactions were stopped by the addition of loading buffer 
and 48 mM DTT followed promptly by freezing at -20 °C.   
Phosphatase assays.  Assay conditions were adapted from published methods (Gowans, 
Hawley, Ross, & Hardie, 2013).  In short, the final assay buffer was comprised of 50 mM Tris 
(pH 7.5), 2.5 MgCl2, 0.01% Triton X-100, 1 mM DTT, and 0.45% DMSO (vehicle).   Because 
some analogs had poor solubility at high concentrations, all analogs and controls were diluted in 
assay buffer and centrifuged (1 min, 5000 rpm, 4 °C) to remove insoluble matter.  PP2C and p-
AMPK were added to the supernatant at final concentrations of 2 and 3 ng/µL, respectively.  
Phosphatase reactions were allowed to proceed for 30 minutes at 37 °C.  Reactions were stopped 
by the addition of loading buffer and 48 mL DTT followed promptly by freezing at -20 °C.   
Cell-intact assays.  HEK cells were grown in DMEM with 10% FBS and 1% 
penicillin/streptomycin at 37 °C.  A subset of plates was serum-starved for 5 hr on the day of the 
experiment.  After 5 hr of serum-starvation, cells were treated with either controls or small 
molecules in the absence of serum for an additional hour prior to lysis.  Vehicle controls were 
treated with 0.2% DMSO.  Another subset of plates was serum-starved for 6 hr and then treated 
with either controls or small molecules for 1 hr in the presence of 10% FBS.  A time course of 
both AMPK and ACC phosphorylation in HEK cells during serum starvation has already been 
published (Pirkmajer & Chibalin, 2011).   
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After incubating in the presence of drugs for one hour, cells were washed 3 times with 
ice-cold PBS and lysed according to published methods (Kazgan, Williams, Forsberg, & 
Brenman, 2010).  Lysates were centrifuged at 16,000 g (10 minutes, 4 °C).  Clarified supernatant 
(30 µL) was then transferred to 10 µL 4X loading buffer and 2 µL 1 M DTT.  Samples were 
immediately frozen at -20 °C.  The concentration of protein in diluted clarified supernatant was 
calculated using a DC protein assay kit (BioRad) prior to western analyses.      
Western analyses.  Protein samples were boiled for 15 minutes in loading buffer and DTT 
prior to SDS-PAGE.  Blots for protein-based assays were sequentially incubated with the 
following: 5% BSA in 1x TBS (1 hr, 22 °C), 1:1000 rabbit anti-human p-AMPK-α antibody or 
p-ACC antibody (2 hr, 22 °C), and 1:10,000 donkey anti-rabbit secondary antibody (1 hr, 22 °C).  
Blots for phosphatase assays were probed a second time using 1:100 mouse anti-human total 
AMPK antibody (overnight, 4 °C; from UNC Antibody Core Facility) followed by 1:10,000 
donkey anti-mouse secondary antibody (1 hr, 22 °C).  Blots for clarified cell lysates were 
sequentially probed for p-AMPK (1:500 dilution, overnight at 4 °C or 4 hr at 22 °C), total ACC 
(1:1000 dilution, overnight at 4 °C or 4 hr at 22 °C), and tubulin (1:10,000 dilution, 1 hr, 22 °C); 
a parallel set of blots were probed for p-ACC (1:500 dilution, overnight at 4 °C or 4 hr at 22 °C), 
total AMPK (1:1000 dilution, overnight at 4 °C or 4 hr at 22 °C), and tubulin (1:10,000 dilution, 
1 hr, 22 °C). Because phosphorylated and total protein were imaged on separate membranes, the 
signals were normalized to the internal tubulin signal prior to calculating the ratio of 
phosphorylated to total protein.  Scanning and imaging were completed according to published 
methods (Kazgan, et al., 2010).   
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Data analysis.  GraphPad Prism was used to fit dose response data for binding assays.  
Instant JChem (ChemAxon LLC, Cambridge, MA) was used to curate data for over 13,000 
molecules that were tested herein and in a previous publication (Sinnett, et al., 2013).  
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Results 
We previously identified molecules that dose-dependently inhibited the protein-bound 
signal of MANT-ADP in the presence of full-length AMPK and the AMPK regulatory fragment 
(Sinnett, et al., 2013).  To determine if these molecules are thiol-reactive, we repeated these 
binding assays in the presence and absence of DTT (Table 3.1).  STK740822 produced similar 
binding curves in the presence of 0-1 mM DTT, suggesting that STK740822 is not thiol-reactive 
(Table 3.1).  STL035166, however, provided a dramatically different dose response curve in the 
presence of 1 mM DTT, with an extrapolated IC50 of ~250 µM (Table 3.1).  Because thiol-
reactive molecules may be promiscuous and therefore undesirable for drug development, 
subsequent orthogonal assays were limited to the characterization of STK740822 and its 
structural analogs.  
To identify analogs of STK740822 and improve the likelihood of discovering a novel 
AMPK modulator, we conducted a small-scale, automated similarity screen of molecules 
containing sub-structural scaffolds present in the parent molecule STK740822 (Fig. 3.1A).  
Three molecules (BAS 02250954, BAS 03338548, and BAS 00502779) reproducibly inhibited 
the protein-bound signal of MANT-ADP (Fig. 3.1A).  To confirm these hits, we re-purchased the 
molecules and determined the binding IC50s in the presence of full-length AMPK (Fig. 3.1B).  
BAS 02250954 and BAS 0333858 dose-dependently inhibited MANT-ADP’s protein-bound 
signal with IC50s that were less than 5 µM.  At high concentrations, however, these molecules 
inhibited MANT-ADP’s fluorescent signal by more than 100%, suggesting that these molecules 
may decrease MANT-ADP’s signal by directly interacting with the probe.  To determine if these 
molecules were directly interacting with the probe, we repeated the binding assays with 0 µM 
AMPK (Fig. 3.1C).  At concentrations approaching 100 µM, these molecules interfered slightly 
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with MANT-ADP’s unbound signal.  Extremely high concentrations of these molecules, 
however, would not be tested in protein- or cell-based assays.  We therefore decided to continue 
testing analogs in subsequent orthogonal assays with the intention of highlighting molecules that 
regulate AMPK activity at low doses.   
To rationally synthesize additional analogs, we first generated a preliminary R group 
decomposition table that ranked positive and negative hits from the similarity screen and a 
previously published high-throughput screen (Sinnett, et al., 2013).  Molecules were ranked 
according to binding IC50s.  The R group decomposition analysis revealed that non-thiol-
reactive positive hits had a common structural scaffold consisting of rhodanine and phenyl-furan 
moieties (Fig. 3.1A inset).  To generate new hits, additional analogs containing this scaffold 
were synthesized.  Synthesized analogs inhibited binding of MANT-ADP in the presence of full-
length AMPK and the regulatory fragment (Table 3.2, Supplementary Table 3.1).  To validate 
the methods for chemical synthesis, STK740822 was synthesized and tested in a binding assay 
with full-length AMPK.  The synthesized control produced a similar binding IC50 (9 µM) and 
Hill Slope (1.2) compared to those of the commercially available molecule (Table 3.2).  The 
panel of analogs yielded similar binding curves in the presence of 0-1 mM DTT (Table 3.2).  
Both 0 and 1 mM DTT conditions were tested in parallel on the same plate.  Likewise, molecules 
yielded similar binding curves in the presence of 0-0.01% Triton X-100 (tested in parallel on the 
same plate) (Supplementary Table 3.2).  Thus, these analogs are most likely neither thiol-
reactive nor small molecule aggregators. 
Interestingly, many analogs exhibited much lower binding IC50s in the presence of the 
regulatory fragment (Table 3.2, Supplementary Table 3.1).  This observation was particularly 
striking because the positive control ADP, which binds 2 sites on AMPK-γ, has the same binding 
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IC50 for both full-length AMPK and the regulatory fragment in the MANT-ADP assay (Fig. 2A-
B).  Because a greater concentration of each analog is needed to displace MANT-ADP from full-
length AMPK, we wondered if the analogs were binding additional sites that may be present on 
full-length AMPK but not on the regulatory fragment.  Theoretically, a mixed agonist/antagonist 
that binds multiple sites with differential affinities could be expected to have a U-shaped dose 
response curve in an enzyme activity assay.  We therefore decided to carefully test each analog 
at multiple doses to identify non-linear dose-dependent regulation of AMPK activity, limiting 
our selection of analogs to those with binding IC50s less than 10 µM.   
Two analogs (100-196, and STK823366) dose-dependently inhibited the activity of 
purified p-AMPK (Fig. 33.A).  At 40 µM, these 2 analogs significantly decreased the yield of p-
GST-ACC peptide (p ≤ 0.05, compared to DMSO control) and achieved a level of inhibition 
similar to that of 40 µM Compound C, a promiscuous kinase inhibitor (Sinnett & Brenman, 
2014).  Interestingly, the analog BAS 02250954 significantly inhibited substrate phosphorylation 
at low doses (p ≤ 0.05, compared to DMSO control), but permitted substrate phosphorylation at 
higher doses (Fig. 3.3B).  Indeed, when we repeated this experiment with an additional 
concentration at 1µM, we saw a complete U-shaped dose response with high levels of p-GST-
ACC peptide produced in the presence of both 1 and 40 µM BAS 02250954 (data not shown).  
Two other analogs (100-202, 123-1) appeared to dose-dependently regulate AMPK activity, but 
not significantly.  The remainder of the analogs tested had no dose-dependent effects on AMPK 
activity at 5, 20, or 40 µM (data not shown). 
The U-shaped dose response curve for BAS 02250954 suggested that the analog may 
exert multiple regulatory effects that oppose each other.  To determine if BAS 02250954 could 
protect p-AMPK from dephosphorylation, we tested the analog in the presence of both p-AMPK 
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and PP2C and then quantified p-AMPK and t-AMPK levels via western analyses (Fig. 3.4).  
After calculating the ratio of the signal intensities for p-AMPK and total AMPK, the ratios were 
normalized to that of the no-PP2C control.  Both BAS 02250954 and its closest structural analog, 
100-196, protected p-AMPK from dephosphorylation (Fig. 3.4).  Furthermore, the level of 
protection provided by these 2 analogs was greater than or similar to that provided by 200 µM 
ADP.  In addition, BAS 02250954 protected p-AMPK at doses that were also shown to restore p-
AMPK activity in the in vitro kinase assays.  In contrast, the more distant structural analog BAS 
03338548 failed to protect p-AMPK from dephosphorylation (Fig. 3.4).  None of the remaining 
analogs from Table 3.2 protected p-AMPK at 3, 10, and 30 µM (data not shown).  The in vitro 
data collected thus far suggests that the dose-dependent modulators identified in Fig. 3.3 may 
regulate AMPK via multiple regulatory mechanisms and perhaps via multiple binding sites.  
Because mechanistic studies (e.g., crystallography) can be labor-intensive, we decided to first 
test our analogs on cells.  Analogs that regulate AMPK in intact cells should be prioritized for 
crystallography (to pinpoint binding sites) or isothermal titration calorimetry (to enumerate 
binding sites and calculate dissociation constants).   
To rigorously determine if analogs regulate AMPK activity in cells, we decided to treat 
HEK cells cultured in media conditions that induce high, moderate, or low p-AMPK levels in the 
absence of drugs.  Serum-starved HEK cells have high endogenous AMPK activity and are 
therefore ideal for identifying novel inhibitors (Pirkmajer & Chibalin, 2011).  In contrast, HEK 
cells continuously cultured in the presence of 10% serum have moderate AMPK activity, 
showing modest decreases in p-ACC levels upon treatment with the non-specific AMPK 
inhibitor Compound C (Figs. 3.5-6).  In agreement with the results from protein-based assays, 
STK823366 decreased phosphorylation of the AMPK substrate ACC in serum-starved cells and 
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serum-treated cells (Figs. 3.5-6).  The positive control, Compound C, achieved the best 
inhibition in serum-starved cells, in contrast to serum-treated cells (Figs. 3.5-6).  Similar to 
STK823366, BAS 02250954 decreased substrate phosphorylation in adherent, serum-treated 
cells (Fig. 3.6).  In the absence of serum, however, treatment with BAS 02250954 caused many 
cells to detach from tissue culture plates.  Cell lysates were not collected from floating cells.  In 
light of the loss of cell adhesion induced by BAS 02250954, we decided to prioritize STK823366 
for further study.   
Before eliminating BAS 02250954, however, we tested this analog on cells that were 
subjected to a cycle of serum starvation followed by restoration of 10% serum (Fig. 3.7).  Cells 
that have been pre-conditioned in this manner have extremely low p-AMPK levels and are ideal 
for the identification of novel activators.  Because BAS 02250954 inhibited purified p-AMPK 
activity but protected purified p-AMPK from dephosphorylation, we expected this analog to de-
couple AMPK phosphorylation from activation in pre-conditioned HEK cells (Figs. 3.3-4,7).  
Indeed, pre-conditioned HEK cells treated with BAS 02250954 for 1 hour in the presence of 
serum had high levels of p-AMPK with no change in substrate phosphorylation.  In contrast, the 
AMP-mimetic A-769662 increased both p-AMPK and p-ACC levels.   
Whereas BAS 02250954 and STK823366 gave consistent results in both protein-based 
and cell-based assays, analog 100-196 unexpectedly increased levels of p-ACC in serum-starved 
HEK cells (Fig. 3.5).  The failure of 100-196 to consistently inhibit substrate phosphorylation in 
both protein-based and cell-based assays further supports the characterization of STK823366 in 
future cell-based studies and the use of STK823366 as a tool compound for protein-based assays. 
Table 3.3 summarizes the conclusions drawn from the various assays described herein.      
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Table 3.1.  Thiol-reactivity. 
 
Data points shown are mean ± σ.  n = 3. 
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Fig. 3.1.  Triplicate similarity screen.  (A). Analogs that reproducibly inhibited MANT-ADP’s protein-bound signal 
are highlighted in red.  These 3 analogs contain a common scaffold (inset structure) and were screened at a final 
concentration of 45 µM.  (B) Parallel dose responses for analogs of STK740822.  Data shown are mean % inhibition 
of MANT-ADP’s protein-bound signal ± σ.  n = 3.    (C) To demonstrate direct interference with the fluorescent 
probe, we plotted the mean % decrease of MANT-ADP’s unbound signal in the presence of various analogs.  The 
background signal of the assay buffer0 µM MANT-ADP, 0 µM AMPK, 0 µM analog) was used to define 100% 
inhibition.  n = 2.  
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Table 3.2.  Binding in the presence of full-length AMPK. 
 
n = 3.  Data are mean ± σ.  *100-205 has a methyl group meta to R2.  All other analogs have a hydrogen meta to R2.  
The binding curves shown above for STK740822 include those of the commercially available analog (black and 
dashed curves) and the synthesized molecule (blue curve). Blind testing of the synthesized STK740822 helped to 
validate the general methods used for analog syntheses. 
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Fig. 3.2.  (A) Isothermal titration calorimetry was used to confirm that ADP binds 2 sites on full-length His-AMPK.  
The calculated dissociation constants (13 µM at both sites) are similar to published dissociation constants of 10 ± 2 
µM (both sites) for MANT-AMP in the presence of AMPK in 25 mM Tris (pH 8) (Xiao, et al., 2007).  n = 1.  (B) 
The same concentration of ADP can be used to displace MANT-ADP from both full-length AMPK and the 
regulatory fragment.  (C) A greater concentration of BAS02250954 is needed to displace MANT-ADP from full-
length AMPK.  (B-C)  Binding of ADP and BAS02250954 to the regulatory fragment and full-length AMPK was 
compared in parallel on one 384-well plate.  n = 3.  Data points shown are mean ± σ.  FL, full-length AMPK.  RF, 
regulatory fragment.    
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Fig. 3.3. Dose-dependent inhibition of purified p-AMPK.  (A) Two analogs inhibit phosphorylation of GST-ACC 
peptide by p-AMPK.  (B) At low concentrations, BAS 02250954 inhibits substrate phosphorylation.  The loss of 
inhibition at higher concentrations is not due to precipitation because the drug remains soluble at 40 µM.  (A-B) The 
promiscuous inhibitor Compound C inhibits substrate phosphorylation.  * p ≤ 0.05, compared to DMSO control. 
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Fig. 3.4. Phosphatase assays.  Two analogs dose-dependently protect p-AMPK from dephosphorylation in the 
presence of PP2C.  None of the remaining analogs, including BAS 03338548 shown above, protected p-AMPK from 
dephosphorylation.  The positive control ADP partially protects p-AMPK from dephosphorylation.   
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Fig. 3.5.  BAS 02250954 and STK823366 appear to modulate p-ACC levels in serum-starved HEK cells.  (A)  
Western blots of cell lysates.  Lysates were collected from adherent cells only.  The p-ACC bands for STK823366-
treated cells are boxed.  (B) Ratios of phospho-protein (normalized to internal tubulin control) to total protein 
(normalized to internal tubulin control).  Data points are mean ± σ and were scaled so that the ratio for DMSO = 
1.00.  One of the 2 data points for 100-196 was discarded because the t-ACC signal could not be accurately 
quantified.  CC, Compound C. 
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Fig. 3.6.  STK823366 decreases p-ACC levels in serum-treated HEK cells.  (A)  Western blots of cell lysates.  The 
p-ACC bands for STK823366-treated cells are boxed.  (B) Ratios of phospho-protein (normalized to loading 
control) to total protein (normalized to loading control).  Data points are mean ± σ and were scaled so that the ratio 
for DMSO = 1.00.  CC, Compound C. 
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Fig. 3.7.  BAS 02250954 does not increase p-ACC levels in pre-conditioned HEK cells.  (A) Western blots of cell 
lysates.  (B)  Ratios of phospho-protein (normalized to loading control) to total protein (normalized to loading 
control).  Data points are mean ± σ and were scaled so that the ratio for DMSO = 1.00. One of the 2 data points for 
DMSO was discarded because the p-AMPK signal could not be accurately quantified.   
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Table 3.3.  Summary of results.
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Supplementary Table 3.1.  Binding to the regulatory fragment. 
 
n = 3.  Data are mean ± σ.  *100-205 has a methyl group meta to R2.  All other analogs have a hydrogen meta to R2.   
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Supplementary Table 3.2.  Detergent sensitivity. 
  
n = 3.  Data are mean ± σ.  *100-205 has a methyl group meta to R2.  All other analogs have a hydrogen meta to R2.   
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Supplementary Fig. 3.1.  Elimination of positive hit identified by published assay (Sinnett, et al., 2013).  In the 
presence of full-length AMPK, the binding curve for Z64358107 is unstable over time. In addition, this molecule 
contains a catechol sub-structure that has been associated with thiol-reactivity (Lipton, 2007).  Data points are mean 
± σ.  n = 3.    
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CHAPTER 4: SUMMARY AND FUTURE DIRECTIONS 
 
We previously published the design of a high-throughput binding assay biased toward the 
identification of molecules that bind the regulatory region of AMPK (Sinnett, Sexton, & 
Brenman, 2013).  In addition to describing the design, optimization, and validation of the assay, 
we identified 3 molecules that dose-dependently displaced a fluorescent probe from binding to 
the AMPK regulatory region (Sinnett, et al., 2013).  One of these positive hits, molecule 
STK740822, produced similar sigmoidal binding curves in the presence of detergent and a 
reducing agent, suggesting that this molecule is a true positive inhibitor of MANT-ADP (Tables 
3.1-2, Supplementary Table 3.2).  The remaining positive hits were eliminated for potential 
thiol-reactivity and unstable binding curves (Table 3.1 and Supplementary Fig 3.1.) 
To improve the likelihood of discovering a novel AMPK drug, we generated a panel of 
synthesized and commercially available analogs that are structurally similar to STK740822 
(Table 3.2).  All of these analogs dose-dependently inhibited the protein-bound signal of 
MANT-ADP in the presence of full-length AMPK and the AMPK regulatory fragment (Table 
3.2, Supplementary Table 3.1).  After carefully testing analogs in protein- and cell-based 
assays, we identified one analog (STK823366) that consistently inhibited AMPK activity without 
  
1This thesis will be embargoed for two years so that the research described in Chapters 3-4 can 
first be published in a journal.    
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inducing loss of cell adhesion (Figs. 3.3, 5-6).  We also identified a molecule (BAS 02250954) 
that inhibits activity at low micromolar concentrations while protecting p-AMPK from 
dephosphorylation at higher concentrations (Figs. 3.3-4).  Interestingly, BAS 02250954 was 
shown to have a U-shaped dose response curve in purified kinase assays, yielding high levels of 
p-GST-ACC peptide at 1 and 40 µM (Fig. 3.3 and data not shown).  The analog’s unusual 
dose-dependent regulation of AMPK activity will most likely limit BAS 02250954’s usefulness 
as a tool compound.  Nevertheless, the characterization of STK823366 and BAS 02250954 
validates the use of our fluorescence-based binding assay as a tool for the discovery of new 
molecules that modulate AMPK activity through multiple regulatory mechanisms.   
Instead of testing our entire panel of analogs on cells, we sequentially narrowed our 
selection of analogs based on binding IC50s, dose-dependent regulation of purified kinase 
activity, and dose-dependent protection of pT172.  We then selected 4 molecules to test on cells.    
One potential limitation of our kinase assay is the use of His-AMPK purified from E. coli.  Some 
researchers prefer to use AMPK purified from rat liver because it is more sensitive to allosteric 
activation in kinase assays (Gowans, Hawley, Ross, & Hardie, 2013).  By preparing frozen 
aliquots of His-tagged AMPK, however, we were able to collect reproducible, comparable data 
for analogs that were synthesized at different times.  In addition, our extremely high-yield 
purification methods allowed us to collect ample protein to optimize assays and to test analogs at 
multiple doses in replicates (Sinnett, et al., 2013).  Ultimately, we identified a novel inhibitor that 
consistently inhibits the activity of both His-AMPK from E. coli and endogenous AMPK in HEK 
cells.   
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It is important for the reader to note that our panel of analogs does not distinguish 
between molecules that have E or Z configurations about the double bond located between the 
furan and rhodanine moieties (Fig. 3.1 inset, Table 3.2).  Although one configuration may be 
thermodynamically favored during synthesis, we did not attempt to separate and characterize 
geometric isomers.  If STK823366 is shown to dose-dependently regulate multiple AMPK 
targets via direct inhibition of AMPK in multiple cell lines, then it may be worthwhile to purify 
geometric isomers and confirm if either or both are biologically active.  In addition to confirming 
the regulatory effects of STK823366 in multiple cell lines, the analog should also be tested 
against AMPK-related kinases.  Similar testing for off-target effects was previously done for the 
β1-selective AMPK activator A-769662 (Goransson, et al., 2007).    
If STK823366 is eventually shown to dose-dependently regulate AMPK in cells without 
regulating AMPK-related kinases, researchers should then identify the mechanism by which 
STK823366 inhibits AMPK.  For example, why are different concentrations of STK823366 
needed to displace MANT-ADP from binding to full-length AMPK and the regulatory fragment 
(Table 3.2 and Supplementary Table 3.1)?  Theoretically, it could be possible for an inhibitor 
to bind the kinase active site and additional sites on the AMPK regulatory region.  Although 
other explanations may exist, the ultimate way to pinpoint the binding sites of STK823366 is to 
do so crystallographically.  ITC could then be used to support the data by confirming the number 
of binding sites.  
 
Conclusion 
 We have used protein- and cell-based assays to characterize analogs of STK740822, a 
molecule that displaces a fluorescent ADP analog from binding to the regulatory region of 
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AMPK.  One of those analogs (STK823366) inhibited the activity of both purified His-AMPK 
and endogenous AMPK in intact HEK cells. The regulatory effects of STK823366 should be 
confirmed in other cell lines.  To determine if this molecule is more selective than Compound C, 
STK823366 should be tested against a panel of kinases, particularly AMPK-related kinases.  
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